U.S. patent application number 14/460188 was filed with the patent office on 2014-12-04 for solid carriers for improved delivery of active ingredients in pharmaceutical compositions.
The applicant listed for this patent is Lipocine Inc.. Invention is credited to Mahesh V. Patel.
Application Number | 20140357586 14/460188 |
Document ID | / |
Family ID | 23777347 |
Filed Date | 2014-12-04 |
United States Patent
Application |
20140357586 |
Kind Code |
A1 |
Patel; Mahesh V. |
December 4, 2014 |
Solid Carriers for Improved Delivery of Active Ingredients in
Pharmaceutical Compositions
Abstract
The present invention provides solid pharmaceutical compositions
for improved delivery of a wide variety of pharmaceutical active
ingredients contained therein or separately administered. In one
embodiment, the solid pharmaceutical composition includes a solid
carrier, the solid carrier including a substrate and an
encapsulation coat on the substrate. The encapsulation coat can
include different combinations of pharmaceutical active
ingredients, hydrophilic surfactant, lipophilic surfactants and
triglycerides. In another embodiment, the solid pharmaceutical
composition includes a solid carrier, the solid carrier being
formed of different combinations of pharmaceutical active
ingredients, hydrophilic surfactants, lipophilic surfactants and
triglycerides. The compositions of the present invention can be
used for improved delivery of hydrophilic or hydrophobic
pharmaceutical active ingredients, such as drugs, nutritional
agents, cosmeceuticals and diagnostic agents.
Inventors: |
Patel; Mahesh V.; (Salt Lake
City, UT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Lipocine Inc. |
Salt Lake City |
UT |
US |
|
|
Family ID: |
23777347 |
Appl. No.: |
14/460188 |
Filed: |
August 14, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12326711 |
Dec 2, 2008 |
|
|
|
14460188 |
|
|
|
|
11196805 |
Aug 2, 2005 |
|
|
|
12326711 |
|
|
|
|
10428341 |
May 1, 2003 |
6923988 |
|
|
11196805 |
|
|
|
|
09800593 |
Mar 6, 2001 |
6569463 |
|
|
10428341 |
|
|
|
|
09447690 |
Nov 23, 1999 |
6248363 |
|
|
09800593 |
|
|
|
|
Current U.S.
Class: |
514/29 ; 514/178;
514/220; 514/221; 514/230.2; 514/254.04; 514/312; 514/454 |
Current CPC
Class: |
A61P 9/04 20180101; A61K
31/5383 20130101; A61K 31/496 20130101; A61P 25/22 20180101; Y02A
50/30 20180101; A61P 25/28 20180101; A61P 43/00 20180101; A61P
17/12 20180101; A61P 9/12 20180101; A61P 37/06 20180101; A61K
31/568 20130101; A61P 1/04 20180101; A61P 7/10 20180101; A61P 9/06
20180101; A61P 21/02 20180101; A61P 5/24 20180101; A61P 5/16
20180101; A61K 9/5026 20130101; A61K 31/7048 20130101; A61P 3/06
20180101; A61P 7/02 20180101; A61P 19/10 20180101; A61P 33/06
20180101; A61K 47/10 20130101; A61P 19/06 20180101; A61P 13/08
20180101; A61P 25/16 20180101; A61P 25/04 20180101; A61K 9/5078
20130101; Y10S 977/906 20130101; Y10S 977/927 20130101; A61P 31/10
20180101; A61P 25/20 20180101; A61P 29/00 20180101; Y02A 50/463
20180101; A61K 9/1676 20130101; A61P 25/06 20180101; A61P 25/26
20180101; A61P 35/00 20180101; A61P 15/10 20180101; A61K 9/4858
20130101; A61K 31/5513 20130101; A61K 31/352 20130101; A61K 9/5084
20130101; A61P 9/10 20180101; A61P 25/08 20180101; A61P 3/04
20180101; A61K 9/1617 20130101; A61P 5/40 20180101; A61K 31/4709
20130101; A61P 3/10 20180101; A61K 9/5015 20130101; A61P 33/10
20180101; A61K 47/14 20130101; A61P 31/12 20180101; B82Y 5/00
20130101; A61P 31/04 20180101 |
Class at
Publication: |
514/29 ; 514/178;
514/254.04; 514/220; 514/312; 514/221; 514/454; 514/230.2 |
International
Class: |
A61K 31/7048 20060101
A61K031/7048; A61K 31/496 20060101 A61K031/496; A61K 31/5383
20060101 A61K031/5383; A61K 31/4709 20060101 A61K031/4709; A61K
31/352 20060101 A61K031/352; A61K 31/568 20060101 A61K031/568; A61K
31/5513 20060101 A61K031/5513 |
Claims
1. A pharmaceutical composition in the form of a solid carrier,
said composition comprising, at least two components selected from
the group consisting of a pharmaceutical active ingredient; a
hydrophilic surfactant, and a lipophilic component, wherein the
pharmaceutical active ingredient is selected from the group
consisting of testosterone undecanoate, ziprasidone, clozapine,
cilostazol, clonazepam, dronabinol, clarithromycin, levofloxacin,
and their pharmaceutically acceptable salts.
2. The pharmaceutical composition of claim 1, wherein the
composition includes a hydrophilic surfactant and the hydrophilic
surfactant is ionic or non-ionic.
3. The pharmaceutical composition of claim 1, wherein the
composition includes a hydrophilic surfactant having an HLB value
of at least 10.
4. The pharmaceutical composition of claim 1, wherein the
composition includes a hydrophilic surfactant selected from the
group consisting of lauryl macrogolglycerides; polyethylene glycol
fatty acids esters; polyethylene glycol glycerol fatty acid esters;
polyoxyethylene sorbitan fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; polyglycerol
fatty acid esters; polyoxyethylene glycerides; polyoxyethylene
vegetable oils; polyoxyethylene hydrogenated vegetable oils;
reaction mixtures of polyols and at least one member of the group
consisting of fatty acids, glycerides, vegetable oils, hydrogenated
vegetable oils, and sterols; tocopherol polyethylene glycol
succinates; sugar esters; fatty acid derivatives of amino acids,
carnitines, oligopeptides, and polypeptides; glyceride derivatives
of amino acids, oligopeptides, and polypeptides; acyl lactylates;
mono-, diacetylated tartaric acid esters of mono-, diglycerides;
succinylated monoglycerides; citric acid esters of mono-,
diglycerides; alginate salts; propylene glycol alginate; lecithins
and hydrogenated lecithins; salts of alkylsulfates; salts of fatty
acids; sodium docusate; and mixtures thereof.
5. The pharmaceutical composition of claim 2, wherein the
hydrophilic surfactant is selected from the group consisting of
polyethylene glycol fatty acids esters; polyethylene glycol
glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid
esters; polyoxyethylene-polyoxypropylene block copolymers;
polyglyceryl fatty acid esters; polyoxyethylene glycerides;
polyoxyethylene vegetable oils; polyoxyethylene hydrogenated
vegetable oils; and tocopherol polyethylene glycol succinates.
6. The pharmaceutical composition of claim 4, wherein the
hydrophilic surfactant is selected from the group consisting of
PEG-20 sorbitan monolaurate; PEG-20 sorbitan monooleate;
polyglyceryl-10 laurate; polyglyceryl-10 monooleate,
polyglycerol-10 dioleate and mixtures thereof; polyglyceryl-10
stearate; polyglyceryl-10 linoleate; PEG-8 caprylic/capric
glycerides; PEG-40 hydrogenated castor oil; PEG-35 castor oil; and
tocopheryl PEG-1000 succinate.
7. The pharmaceutical composition of claim 2, wherein the
hydrophilic surfactant is selected from the group consisting of
lecithin, lactylic esters of fatty acids, stearoyllactylate,
succinylated monoglycerides, monoacetylated and diacetylated
tartaric acid esters of monoglycerides and diglycerides, citric
acid esters of monoglycerides and diglycerides, taurocholate,
caprylate, caprate, oleate, lauryl sulfate, docusate, and salts and
mixtures thereof.
8. The pharmaceutical composition of claim 1, wherein the
composition includes a hydrophilic surfactant and the hydrophilic
surfactant represents 2.4% w/w to 76% w/w of the solid carrier.
9. The pharmaceutical composition of claim 1, wherein the
composition includes hydrophilic surfactant and the hydrophilic
surfactant 12.1% w/w to 76% w/w of the solid carrier.
10. The pharmaceutical composition of claim 1, wherein the
composition is formulated for immediate release.
11. The pharmaceutical composition of claim 1, wherein the
composition is formulated for pulsatile release, controlled
release, extended release, delayed release, targeted release, or
targeted delayed release.
12. The pharmaceutical composition of claim 1, wherein the
composition is in the form of a capsule, a tablet, a granule, a
pellet, or a bead.
13. The pharmaceutical composition of claim 12, wherein the
lipophilic component is a lipophilic surfactant or a
triglyceride.
14. The pharmaceutical composition of claim 1, wherein the
composition includes a lipophilic component having an HLB value of
less than 10.
15. The pharmaceutical composition of claim 12, wherein the
lipophilic component is selected from the group consisting of
triglycerides; fatty acids; lower alcohol fatty acid esters;
polyethylene glycol glycerol fatty acid esters; polypropylene
glycol fatty acid esters; polyoxyethylene glycerides; glycerol
fatty acid esters; acetylated glycerol fatty acid esters; lactic
acid derivatives of mono/diglycerides; sorbitan fatty acid esters;
polyoxyethylene sorbitan fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; polyoxyethylene
vegetable oils; polyoxyethylene hydrogenated vegetable oils; and
reaction mixtures of polyols and fatty acids, glycerides, vegetable
oils, hydrogenated vegetable oils, and sterols.
16. The pharmaceutical composition of claim 12, wherein the
lipophilic component is selected from the group consisting of
glyceryl laurate; glyceryl stearate; glyceryl monooleate; glycerol
monostearate; glyceryl monostearate; glycerol monolinoleate;
sorbitan monooleate; sorbitan monolaurate; polyglyceryl-2 oleate;
polyglyceryl-2 stearate; polyglyceryl-2 isostearate; polyglyceryl-3
oleate; polyglyceryl-4 oleate; polyglyceryl-4 stearate;
polyglyceryl-6 oleate; polyglyceryl-3 dioleate; polyglyceryl-3
distearate; polyglyceryl-4 pentaoleate; polyglyceryl-6 dioleate;
polyglyceryl-2 dioleate; polyglyceryl-10 trioleate; polyglyceryl-10
tetraoleate.
17. The pharmaceutical composition of claim 1, wherein the
composition also includes an additive selected from the group
consisting of natural or synthetic waxes and polymers.
18. The pharmaceutical composition of claim 17, wherein the
additive is a selected from the group consisting of natural or
synthetic waxes.
19. The pharmaceutical composition of claim 17, wherein the
additive is a polymer.
20. The pharmaceutical composition of claim 19, wherein the polymer
is selected from the group consisting of polyvinylpyrrolidone and
cellulose derivatives.
Description
[0001] This application is a continuation of U.S. patent
application Ser. No. 11/196,805, filed Aug. 2, 2005, which is a
continuation-in-part of U.S. patent application Ser. No.
10/428,341, filed on May 1, 2003, now issued as U.S. Pat. No.
6,923,988, which is a continuation of U.S. Ser. No. 09/800,593
filed on Mar. 6, 2001, now issued as U.S. Pat. No. 6,569,463, which
is a divisional of U.S. Ser. No. 09/447,690, filed on Nov. 23,
1999, now issued as U.S. Pat. No. 6,248,363, each of which is
incorporated herein by reference.
FIELD OP TH INVENTION
[0002] The present invention relates to pharmaceutical delivery
systems for pharmaceutical active ingredients, such as drugs,
nutritionals, cosmeceuticals, and diagnostic agents. In particular,
the present invention provides compositions and dosage forms
including solid carriers for improved delivery of pharmaceutical
active ingredients.
BACKGROUND OP THE INVENTION
[0003] Hydrophobic active ingredients, such as progesterone,
cyclosporin, itraconazole and glyburide present delivery challenges
due to their poor aqueous solubility and slow dissolution rate.
Several commercial products of these hydrophobic drugs are
available, the various products using different methods to try to
enhance in vivo performance. One approach is size reduction by
micronization, such as in Prometrium (micronized progesterone) and
Micronase (micronized glyburide). Other approaches include size
reduction in emulsion formulations, such as in Sandimmune
(cyclosporin emulsion) and NeOral (cyclosporin microemulsion).
These approaches suffer from several disadvantages.
Micronization/nanonization presents processing and stability
challenges, as well as dissolution limitations, since the
micronized/nanosized drug still possesses a high degree of
crystallinity. Liquid formulations present drug precipitation and
packaging challenges, due to solvent evaporation. Moreover,
non-solid formulations are more prone to chemical instability and
capsule-shell incompatibility, leading to the possibility of
leakage upon storage.
[0004] For hydrophilic active ingredients, the formulation
challenges are different. Although these compounds are readily
soluble in the aqueous gastrointestinal environment, they are
poorly absorbed, due to poor membrane permeability and/or enzymatic
degradation. Surfactants and lipophilic additives have been
reported to improve membrane permeability; see, e.g., LeCluyse and
Sutton, "In vitro models for selection of development candidates.
Permeability studies to define mechanisms of absorption
enhancement," Advanced Drug Delivery Reviews, 23, 163-183 (1997).
However, these compositions fail to maintain effective levels and
type of enhancers for bioacceptable absorption enhancement. Most
solid dosage forms of hydrophilic active ingredients exhibit poor
or no absorption of the active. Moreover, these non-solid
formulations suffer from the disadvantages of chemical instability,
leakage and capsule shell incompatibility as discussed above.
[0005] Solid carriers for pharmaceutical active ingredients offer
potential advantages over micronized drugs, emulsions or
solubilized formulations. Solid carriers, typically of size less
than about 2 mm, can easily pass through the stomach, thus making
the performance less prone to gastric emptying variability.
Further, the problems of leakage and other disadvantages of liquid
formulations are not present in solid carrier formulations. To
date, however, such solid carrier formulations generally have been
limited to a few specific drugs, due to difficulties in formulating
appropriate drug/excipient compositions to effectively coat the
active ingredient onto a carrier particle.
[0006] Conventional solid dosage forms of hydrophobic active
ingredients, such as tablets, or multiparticulates in capsules,
often exhibit slow and incomplete dissolution and subsequent
absorption. These formulations often show a high propensity for
biovariability and food interactions of the active ingredient,
resulting in restrictive compliance/labeling requirements.
[0007] Due to the slow dissolution and dependence on gastric
emptying, solid dosage forms often delay the onset of some
hydrophobic active ingredients.
[0008] Thus, there is a need for pharmaceutical compositions and
dosage forms, and methods therefor, that do not suffer from the
foregoing disadvantages.
SUMMARY OF THE INVENTION
[0009] It is an object of the invention to provide solid
pharmaceutical compositions having active ingredients in a rapid
dissolvable and more solubilized state therein.
[0010] It is another object of the invention to provide solid
pharmaceutical compositions having more rapid dissolution upon
administration to a patient.
[0011] It is another object of the invention to provide solid
pharmaceutical compositions having more sustained and complete
solubilization upon administration to a patient.
[0012] It is another object of the invention to provide solid
pharmaceutical compositions capable of delivery a wide variety of
pharmaceutical active ingredients.
[0013] It is another object of the invention to provide solid
pharmaceutical compositions of coated substrate materials without
the need for binders.
[0014] It is another object of the invention to provide solid
pharmaceutical compositions having increased chemical stability of
the active ingredient
[0015] It is another object of the invention to provide solid
pharmaceutical compositions capable of improving the absorption
and/or bioavailability of pharmaceutical active ingredients.
[0016] It is another object of the invention to provide solid
pharmaceutical compositions having better protection of the upper
gastrointestinal tract from untoward effects of the active
ingredient.
[0017] It is another object of the present invention to provide
solid pharmaceutical compositions capable of improving the
palatability of or masking the taste of unpalatable pharmaceutical
active ingredients.
[0018] In accordance with these and other objects, the present
invention provides solid pharmaceutical compositions for improved
delivery of a wide variety of pharmaceutical active ingredients
contained therein or separately administered.
[0019] In one embodiment, the solid pharmaceutical composition
includes a solid carrier, the solid carrier including a substrate
and an encapsulation coat on the substrate. The encapsulation coat
includes at least one ionic or non-ionic hydrophilic surfactant.
Optionally, the encapsulation coat can include a pharmaceutical
active ingredient, a lipophilic component such as a lipophilic
surfactant or a triglyceride, or both a pharmaceutical active
ingredient and a lipophilic component.
[0020] In another embodiment, the solid pharmaceutical composition
includes a solid carrier, the solid carrier including a substrate
and an encapsulation coat on the substrate. The encapsulation coat
includes a lipophilic component, such as a lipophilic surfactant or
a triglyceride. Optionally, the encapsulation coat can include a
pharmaceutical active ingredient, an ionic or non-ionic hydrophilic
surfactant, or both a pharmaceutical active ingredient and a
hydrophilic surfactant.
[0021] In another embodiment, the solid pharmaceutical composition
includes a solid carrier, the solid carrier including a substrate
and an encapsulation coat on the substrate. The encapsulation coat
includes a pharmaceutical active ingredient and an ionic or
non-ionic hydrophilic surfactant; a pharmaceutical active
ingredient and a lipophilic component such as a lipophilic
surfactant or a triglyceride; or a pharmaceutical active ingredient
and both a hydrophilic surfactant and a lipophilic component.
[0022] In another embodiment, the solid pharmaceutical composition
includes a solid carrier, wherein the solid carrier is formed of at
least two components selected from the group consisting of
pharmaceutical active ingredients; ionic or non-ionic hydrophilic
surfactants; and lipophilic components such as lipophilic
surfactants and triglycerides.
[0023] In other aspects, the present invention also provides dosage
forms of any of the solid pharmaceutical compositions, and methods
of using the solid pharmaceutical compositions.
[0024] These and other objects and features of the present
invention will become more fully apparent from the following
description and appended claims, or may be learned by the practice
of the invention as set forth hereinafter.
BRIEF DESCRIPTION OF THE DRAWING
[0025] In order to illustrate the manner in which the above-recited
and other advantages and objects of the invention are obtained, a
more particular description of the invention briefly described
above will be rendered by reference to specific embodiments thereof
which are illustrated in the appended drawings. Understanding that
these drawings depict only typical embodiments of the invention and
are not therefore to be considered to be limiting of its scope, the
invention will be described and explained with additional
specificity and detail through the use of the accompanying drawings
in which:
[0026] FIG. 1 is a graph showing the extent of dissolution/release
of glyburide as a function of time for a composition according to
the present invention and two prior art compositions.
[0027] FIG. 2A is a graph showing the extent of dissolution/release
of progesterone as a function of time for two compositions
according to the present invention and the pure bulk drug.
[0028] FIG. 2B is a graph showing the extent of dissolution/release
of progesterone as a function of time for two compositions of the
present invention, a conventional commercial formulation of
progesterone, and the pure bulk drug.
[0029] FIG. 3 is a graph showing the extent of dissolution/release
of omeprazole as a function of time for two compositions according
to the present invention and a prior art composition.
DETAILED DESCRIPTION OF TH INVENTION
[0030] The present invention provides solid pharmaceutical
compositions for improved delivery of a wide variety of
pharmaceutical active ingredients, contained therein or separately
administered. In one embodiment, the solid pharmaceutical
composition includes a solid carrier, the solid carrier including a
substrate and an encapsulation coat on the substrate. The
encapsulation coat can include different combinations of
pharmaceutical active ingredients, hydrophilic surfactants,
lipophilic surfactants and triglycerides. In another embodiment,
the solid pharmaceutical composition includes a solid carrier, the
solid carrier being formed of different combinations of
pharmaceutical active ingredients, hydrophilic surfactants,
lipophilic surfactants and triglycerides. These and other
embodiments, as well as preferred aspects thereof, are described in
more detail below.
[0031] It should be appreciated that any of the components of the
compositions of the present invention can be used as supplied
commercially, or can be preprocessed by agglomeration, air
suspension chilling, air suspension drying, balling, coacervation,
comminution, compression, pelletization, cryopelletization,
extrusion, granulation, homogenization, inclusion complexation,
lyophilization, melting, mixing, molding, pan coating, solvent
dehydration, sonication, spheronization, spray chilling, spray
congealing, spray drying, or other processes known in the art. The
various components can also be pre-coated or encapsulated. These
various processes and coatings are described in more detail
below.
[0032] 1. Pharmaceutical Active Ingredients
[0033] In the embodiments of the present invention, which include
active ingredients, the active ingredients suitable for use in the
pharmaceutical compositions and methods of the present invention
are not particularly limited, as the compositions are surprisingly
capable of effectively delivering a wide variety of active
ingredients. The active ingredients can by hydrophilic, lipophilic,
amphiphilic or hydrophobic, and can be solubilized, dispersed, or
partially solubilized and dispersed, in the encapsulation coat.
Alternatively, the active ingredient can be provided separately
from the solid pharmaceutical composition, such as for
co-administration. Such active ingredients can be any compound or
mixture of compounds having therapeutic or other value when
administered to an animal, particularly to a mammal, such as drugs,
nutrients, cosmeceuticals, diagnostic agents, nutritional agents,
and the like. It should be appreciated that the categorization of
an active ingredient as hydrophilic or hydrophobic may change,
depending upon the particular salts, isomers, analogs and
derivatives used.
[0034] In one embodiment, the active ingredient agent is
hydrophobic. Hydrophobic active ingredients are compounds with
little or no water solubility. Intrinsic water solubilities (i.e.,
water solubility of the unionized form) for hydrophobic active
ingredients are less than about 1% by weight, and typically less
than about 0.1% or 0.01% by weight. In a particular aspect of this
embodiment, the active ingredient is a hydrophobic drug. In other
particular aspects, the active ingredient is a nutrient, a
cosmeceutical, a diagnostic agent or a nutritional agent.
[0035] Suitable hydrophobic active ingredients are not limited by
therapeutic category, and can be, for example, analgesics,
anti-inflammatory agents, antihelminthics, anti-arrhythmic agents,
anti-bacterial agents, anti-viral agents, anti-coagulants,
anti-depressants, anti-diabetics, anti-epileptics, anti-fungal
agent, anti-gout agents, anti-hypertensive agents, anti-malarials,
anti-migraine agents, anti-muscarinic agents, anti-neoplastic
agents, erectile dysfunction improvement agents,
immunosuppressants, anti-protozoal agents, anti-thyroid agents,
anxiolytic agents, sedatives, hypnotics, neuroleptics,
.beta.-blockers, cardiac inotropic agents, corticosteroids,
diuretics, anti-parkinsonian agents, gastro-intestinal agents,
histamine receptor antagonists, keratolytics, lipid regulating
agents, anti-anginal agents, Cox-2 inhibitors, leukotriene
inhibitors, macrolides, muscle relaxants, anti-osteoporosis agents,
anti-obesity agents, cognition enhancers, anti-urinary incontinence
agents, nutritional oils, anti-benign prostate hypertrophy agents,
essential fatty acids, non-essential fatty acids, and mixtures
thereof.
[0036] Specific, non-limiting examples of suitable hydrophobic
active ingredients are: acetretin, albendazole, albuterol,
aminoglutethimide, amiodarone, amlodipine, amphetamine,
amphotericin B, atorvastatin, atovaquone, azithromycin, baclofen,
beclomethasone, benezepril, benzonatate, betamethasone,
bicalutanide, budesonide, bupropion, busulfan, butenafine,
calcifediol, calcipotriene, calcitriol, camptothecin, candesartan,
capsaicin, carbamezepine, carotenes, celecoxib, cerivastatin,
cetirizine, chlorpheniramine, cholecalciferol, cilostazol,
cimetidine, cinnarizine, ciprofloxacin, cisapride, clarithromycin,
clemastine, clomiphene, clomipramine, clopidogrel, codeine,
coenzyme Q10, cyclobenzaprine, cyclosporin, danazol, dantrolene,
dexchlorpheniramine, diclofenac, dicoumarol, digoxin,
dehydroepiandrosterone, dihydroergotamine, dihydrotachysterol,
dirithromycin, donezepil, efavirenz, eprosartan, ergocalciferol,
ergotamine, essential fatty acid sources, etodolac, etoposide,
famotidine, fenofibrate, fentanyl, fexofenadine, finasteride,
fluconazole, flurbiprofen, fluvastatin, fosphenytoin, frovatriptan,
furazolidone, gabapentin, gemfibrozil, glibenclamide, glipizide,
glyburide, glimepiride, griseofulvin, halofantrine, ibuprofen,
irbesartan, irinotecan, isosorbide dinitrate, isotretinoin,
itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine,
lansoprazole, leflunomide, lisinopril, loperamide, loratadine,
lovastatin, L-thyroxine, lutein, lycopene, medroxyprogesterone,
mifepristone, mefloquine, megestrol acetate, methadone,
methoxsalen, metronidazole, miconazole, midazolam, miglitol,
minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine,
naratriptan, nelfinavir, nifedipine, nisoldipine, nilutanide,
nitrofurantoin, nizatidine, omeprazole, oprevelkin, oestradiol,
oxaprozin, paclitaxel, pantoprazole, paracalcitol, paroxctine,
pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone,
probucol, progesterone, pseudoephedrine, pyridostigmine,
rabeprazole, raloxifene, repaglinide, rifabutine, rifapentine,
rimexolone, ritanovir, rizatriptan, rofecoxib, rosiglitazone,
saquinavir, sertraline, sibutramine, sildcnafil citrate,
simvastatin, sirolimus, spironolactone, sumatriptan, tacrine,
tacrolimus, tamoxifen, tamsulosin, targretin, tazarotene,
telmisartan, teniposide, terbinafine, terazosin,
tetrahydrocannabinol, tiagabine, ticlopidine, tirofibran,
tizanidine, topiramate, topotecan, toremifene, tramadol, tretinoin,
troglitazone, trovafloxacin, ubidecarenone, valsartan, venlafaxine,
verteporfin, vigabatrin, vitamin A, vitamin D, vitamin E, vitamin
K, zafirlukast, zileuton, zolmitriptan, zolpidem, and zopiclone. Of
course, salts, isomers and derivatives of the above-listed
hydrophobic active ingredients may also be used, as well as
mixtures thereof.
[0037] Among the above-listed hydrophobic active ingredients,
preferred active ingredients include: acetretin, albendazole,
albuterol, aminoglutethimide, amiodarone, amlodipine, amphetamine,
amphotericin B, atorvastatin, atovaquone, azithromycin, baclofen,
benzonatate, bicalutanide, busulfan, butenafine, calcifediol,
calcipotriene, calcitriol, camptothecin; capsaicin, carbamezepine,
carotenes, celecoxib, cerivastatin, chlorpheniramine,
cholecaliferol, cimetidine, cinnarizine, ciprofloxacin, cisapride,
cetirizine, clarithromycin, clemastine, clomiphene, codeine,
coenzyme Q10, cyclosporin, danazol, dantrolene,
dexchlorpheniramine, diclofenac, digoxin, dehydroepiandrosterone,
dihydroergotamine, dihydrotachysterol, dirithromycin, donezepil,
efavirenz, ergocalciferol, ergotamine, esomeprazole, essential
fatty acid sources, etodolac, etoposide, famotidine, fenofibrate,
fentanyl, fexofenadine, finasteride, fluconazole, flurbiprofen,
fluvastatin, fosphenytoin, frovatriptan, furazolidone, gabapentin,
gemfibrozil, glibenclamide, glipizide, glyburide, glimepiride,
griseofulvin, halofantrine, ibuprofen, irinotecan, isotretinoin,
itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine,
lansoprazole, leflunomide, loperamide, loratadine, lovastatin,
L-thyroxine, lutein, lycopene, mifepristone, mefloquine, megestrol
acetate, methdone, methoxsalen, metronidazole, miconazole,
midazolam, miglitol, mitoxantrone, medroxyprogesterone,
montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir,
nilutanide, nitrofurantoin, nizatidine, omeprazole, oestradiol,
oxaprozin, paclitaxel, paracalcitol, pentazocine, pioglitazone,
pizofetin, pravastatin, probucol, progesterone, pseudoephedrine,
pyridostigmine, rabeprazole, raloxifene, rofecoxib, repaglinide,
rifabutine, rifapentine, rimexolone, ritanovir, rizatriptan,
rosiglitazone, saquinavir, sibutramine, sildenafil citrate,
simvastatin, sirolimus, spironolactone, sumatriptan, tacrine,
tacrolimus, tamoxifen, tamsulosin, targretin, tazarotene,
teniposide, terbinafine, tetrahydrocannabinol, tiagabine,
tizanidine, topiramate, topotecan, toremifene, tramadol, tretinoin,
troglitazone, trovafloxacin, verteporfin, vigabatrin, vitamin A,
vitamin D, vitamin E, vitamin K, zafirlukast, zileuton,
zolmitriptan, zolpidem, zopiclone, pharmaceutically acceptable
salts, isomers and derivatives thereof, and mixtures thereof.
[0038] Particularly preferred hydrophobic active ingredients
include: acetretin, albuterol, aminoglutethimide, amiodarone,
amlodipine, amprenavir, atorvastatin, atovaquone, baclofen,
benzonatate, bicalutanide, busulfan, calcifediol, calcipotriene,
calcitriol, camptothecin, capsaicin, carbamezepine, carotenes,
celecoxib, chlorpheniramine, cholecaliferol, cimetidine,
cinnarizine, cisapride, cetirizine, clemastine, coenzyme Q10,
cyclosporin, danazol, dantrolene, dexchlorpheniramine, diclofenac,
dehydroepiandrosterone, dihydroergotamine, dihydrotachysterol,
efavirenz, ergocalciferol, ergotamine, essential fatty acid
sources, etodolac, etoposide, famotidine, fenofibrate,
fexofenadine, finasteride, fluconazole, flurbiprofen, fosphenytoin,
frovatriptan, furazolidone, glibenclamide, glipizide, glyburide,
glimepiride, ibuprofen, irinotecan, isotretinoin, itraconazole,
ivermectin, ketoconazole, ketorolac, lamnotigine, lansoprazole,
leflunomide, loperamide, loratadine, lovastatin, L-thyroxine,
lutein, lycopene, medroxyprogesterone, mifepristone, megestrol
acetate, methoxsalen, metronidazole, miconazole, miglitol,
mitoxantrone, montelukast, nabumetone, naratriptan, nelfinavir,
nilutanide, nitrofurantoin, nizatidine, omeprazole, oestradiol,
oxaprozin, paclitaxel, paracalcitol, pioglitazone, pizofetin,
pranlukast, probucol, progesterone, pseudoephedrine, rabeprazole,
raloxifene, rofecoxib, repaglinide, rifabutine, rifapentine,
rimexolone, ritanovir, rizatriptan, rosiglitazone, saquinavir,
sildenafil citrate, simvastatin, sirolimus, tacrolimus, tamoxifen,
tamsulosin, targretin, tazarotene, teniposide, terbinafine,
tetrahydrocannabinol, tiagabine, tizanidine, topiramate, topotecan,
toremifene, tramadol, tretinoin, troglitazone, trovafloxacin,
ubidecarenone, vigabatrin, vitamin A, vitamin D, vitamin E, vitamin
K, zafirlukast, zileuton, ziprasidone, zolmitriptan,
pharmaceutically acceptable salts, isomers and derivatives thereof,
and mixtures thereof.
[0039] Most preferred hydrophobic active ingredients include:
amlodipine, amprenavir, anagrelide, aprepitant, aripiprazole,
atorvastatin, atovaquone, bosentan, budesonide, bupropion,
carvedilol, celecoxib, cilostazol, cisapride, clarithromycin,
clozapine, clonazepam, coenzyme Q10, cyclosporin,
dihydroergotamine, dronabinol, efavirenz, entacapone, eplerenone,
eprosartan, estazolam, famotidine, felodipine, fenofibrate,
fexofenadine, finasteride, gatifloxacin, haloperidol, ibuprofen,
imipramine, isradipine, itraconazole, lamotrigine, lansoprazole,
lercanidipine, levofloxacin, loratadine, lovastatin, megestrol
acetate, megestrol acetate, meloxicam, montelukast, nabumetone,
nisoldipine, nizatidine, norfloxacin, olanzapine, omeprazole,
oxandrolone, oxaprozin, oxybutynin, oxycarbazepine, paclitaxel,
paracalcitol, pioglitazone, pranlukast, prednisone, progesterone,
pseudoephedrine, quetiapine, rabeprazole, raloxifene, ramipril,
rapamycin, risperidone, rofecoxib, repaglinide, rimexolone,
ritanovir, ropinirole, rosiglitazone, rufinamide, saquinavir,
sildenafil, sildenafil citrate, simvastatin, sirolimus,
spironolactone, tacrine, tacrolimus, tamoxifen, tamsulosin,
tegaserod, teniposide, testosterone undecanoate, terbinafine,
tetrahydrocannabinol, thalidomide, tiagabine, ticlopidine,
tizanidine, tolcapone, tolterodine, tramadol, troglitazone,
valsartan, vitamin A, vitamin D, vitamin E, vitamin K, zafirlukast,
zileuton, ziprasidone, pharmaceutically acceptable salts, isomers
and derivatives thereof, and mixtures thereof.
[0040] In another embodiment, the active ingredient is hydrophilic.
Amphiphilic compounds are also included within the class of
hydrophilic active ingredients. Apparent water solubilities for
hydrophilic active ingredients are greater than about 0.1% by
weight and typically greater than about 1% by weight. In other
particular aspects, the hydrophilic active ingredient is a
cosmeseutical, a diagnostic agent, or a nutritional agent.
[0041] Suitable hydrophilic active ingredients are not limited by
therapeutic category, and can be, for example, analgesics,
anti-inflammatory agents, antihelminthics, anti-arrhythmic
agents, anti-bacterial agents, anti-viral agents, anti-coagulants,
anti-depressants, anti-diabetics, anti-epileptics, anti-fungal
agent, anti-gout agents, anti-hypertensive agents, anti-malarials,
anti-migraine agents, anti-muscarinic agents, anti-neoplastic
agents, erectile dysfunction improvement agents,
immunosuppressants, anti-protozoal agents, anti-thyroid agents,
anxiolytic agents, sedatives, hypnotics, neuroleptics,
.beta.-blockers, cardiac inotropic agents, corticosteroids,
diuretics, anti-parkinsonian agents, gastro-intestinal agents,
histamine receptor antagonists, keratolytics, lipid regulating
agents, anti-anginal agents, Cox-2 inhibitors, leukotriene
inhibitors, macrolides, muscle relaxants, anti-osteoporosis agents,
anti-obesity agents, cognition enhancers, anti-urinary incontinence
agents, nutritional oils, anti-benign prostate hypertrophy agents,
essential fatty acids, non-essential fatty acids, and mixtures
thereof.
[0042] Likewise, the hydrophilic active ingredients can be a
cytokine, a peptidomimetic, a peptide, a protein, a toxoid, a
serum, an antibody, a vaccine, a nucleoside, a nucleotide, a
portion of genetic material, a nucleic acid, or a mixture
thereof.
[0043] Specific, non-limiting examples of suitable hydrophilic
active ingredients include: acarbose; acyclovir; acetyl cysteine;
acetylcholine chloride; alatrofloxacin; alendronate; alglucerase;
amantadine hydrochloride; ambenomium; amifostine; amniloride
hydrochloride; aminocaproic acid; amphotericin B; antihemophilic
factor (human); antihemophilic factor (porcine); antihemophilic
factor (recombinant); aprotinin; asparaginase; atenolol; atracurium
besylate; atropine; azithromycin; aztreonam; BCG vaccine;
bacitracin; becalermin; belladona; bepridil hydrochloride;
bleomycin sulfate; calcitonin human; calcitonin salmon;
carboplatin; capecitabine; capreomycin sulfate; cefamandole nafate;
cefazolin sodium; cefepime hydrochloride; cefixime; cefonicid
sodium; cefoperazone; cefotetan disodium; cefotaxime; cefoxitin
sodium; ceftizoxime; ceftriaxone; cefuroxime axetil; cephalexin;
cephapirin sodium; cholera vaccine; chorionic gonadotropin;
cidofovir, cisplatin; cladribine; clidinium bromide; clindamycin
and clindamycin derivatives; ciprofloxacin; clodronate;
colistimethate sodium; colistin sulfate; corticotropin;
cosyntropin; cromolyn sodium; cytarabine; dalteparin sodium;
danaparoid; desferrioxamine; denileukin diftitox; desmopressin;
diatrizoate meglumine and diatrizoate sodium; dicyclomine;
didanosine; dirithromycin; dopamine hydrochloride; dornase alpha;
doxacurium chloride; doxorubicin; etidronate disodium; enelaprilat;
enkephalin; enoxaparin; enoxaparin sodium; ephedrine; epinephrine;
epoetin alpha; erythromycin; esmolol hydrochloride; factor IX;
famciclovir; fludarabine; fluoxetine; foscamet sodium; ganciclovir;
granulocyte colony stimulating factor; granulocyte-macrophage
stimulating factor, recombinant human growth hormones; bovine
growth hormone; gentamycin; glucagon; glycopyrolate; gonadotropin
releasing hormone and synthetic analogs thereof; GnRH; gonadorelin;
grepafloxacin; haemophilus B conjugate vaccine; Hepatitis A virus
vaccine inactivated; Hepatitis B virus vaccine inactivated; heparin
sodium; indinavir sulfate; influenza virus vaccine; interleukin-2;
interleukin-3; insulin-human; insulin lispro; insulin procine;
insulin NPH; insulin aspart; insulin glargine; insulin detemir;
interferon alpha; interferon beta; ipratropium bromide; ifosfamide;
Japanese encephalitis virus vaccine; lamivudine; leucovorin
calcium; leuprolide acetate; levofloxacin; lincomycin and
lincomycin derivatives; lobucavir; lomefloxacin; loracarbef;
mannitol; measles virus vaccine; meningococcal vaccine;
menotropins; mepenzolate bromide; mesalamine; methenamine;
methotrexate; methscopolamine; metformin hydrochloride; metoprolol;
mezocillin sodium; mivacurium chloride; mumps viral vaccine;
nedocromil sodium; neostigmine bromide; neostigrnine methyl
sulfate; neurontin; norfloxacin; octreotide acetate; ofloxacin;
olpadronate; oxytocin; pamidronate disodiuni; pancuronium bromide;
paroxetine; perfloxacin; pentamidine isethionate; pentostatin;
pentoxifylline; periciclovir; pentagastrin; phentolamine mesylate;
phenylalanine; physostigmine salicylate; plague vaccine;
piperacillin sodium; platelet derived growth factor; pneumococcal
vaccine polyvalent; poliovirus vaccine (inactivated); poliovirus
vaccine live (OPV); polymyxin B sulfate; pralidoxime chloride;
pramlintide; pregabalin; propafenone; propantheline bromide;
pyridostigmine bromide; rabies vaccine; residronate; ribavarin;
rimantadine hydrochloride; rotavirus vaccine; salmeterol xinafoate;
sincalide; small pox vaccine; solatol; somatostatin; sparfloxacin;
spectinomycin; stavudine; streptokinase; streptozocin;
suxamethonium chloride; tacrine hydrochloride; terbutaline sulfate;
thiopeta; ticarcillin; tiludronate; timolol; tissue type
plasminogen activator; TNFR:Fc; TNK-tPA; trandolapril; trimetrexate
gluconate; trospectinomycin; trovafloxacin; tubocurarine chloride;
tumor necrosis factor; typhoid vaccine live; urea; urokinase;
vancomycin; valacyclovir, valsartan; varicella virus vaccine live;
vasopressin and vasopressin derivatives; vecuronium bromide;
vinblastine; vincristine; vinorelbine; vitamin B12; warfarin
sodium; yellow fever vaccine; zalcitabine; zanamivir; zolendronate;
zidovudine; pharmaceutically acceptable salts, isomers and
derivatives thereof; and mixtures thereof.
[0044] Among the above-listed hydrophilic active ingredients,
preferred active ingredients include acarbose; acyclovir,
atracurium besylate; alendronate; alglucerase; amantadine
hydrochloride; amphotericin B; antihemophilic factor (human);
antihemophilic factor (porcine); antihemophilic factor
(recombinant); azithromycin; calcitonin human; calcitonin salmon;
capecitabine; cefazolin sodium; cefonicid sodium; cefoperazone;
cefoxitin sodium; ceftizoxime; ceftriaxone; cefuroxime axetil;
cephalexin; chorionic gonadotropin; cidofovir; cladribine;
clindamycin and clindamycin derivatives; corticotropin;
cosyntropin; cromolyn sodium; cytarabine; dalteparin sodium;
danaparoid; desmopressin; didanosine; dirithromycin; etidronate
disodium; enoxaparin sodium; epoetin alpha; factor IX; famciclovir;
fludarabine; foscamet sodium; ganciclovir; granulocyte colony
stimulating factor; granulocyte-macrophage stimulating factor;
recombinant human growth hormones; bovine growth hormone;
gentamycin; glucagon; gonadotropin releasing hormone and synthetic
analogs thereof; GnRH; gonadorelin; haemophilus B conjugate
vaccine; Hepatitis A virus vaccine inactivated; Hepatitis B virus
vaccine inactivated; heparin sodium; indinavir sulfate; influenza
virus vaccine; interleukin-2; interleukin-3; insulin-human; insulin
lispro; insulin procine; insulin NPH; insulin aspart; insulin
glargine; insulin detemir; interferon alpha; interferon beta;
ipratropium bromide; ifosfamide; lamivudine; leucovorin calcium;
leuprolide acetate; lincomycin and lincomycin derivatives;
metformin hydrochloride; nedocromil sodium; neostigmine bromide;
neostigmine methyl sulfate; neurontin; octreotide acetate;
olpadronate; pamidronate disodium; pancuronium bromide; pentamidine
isethionate; pentagastrin; physostigmine salicylate; poliovirus
vaccine live (OPV); pyridostigmine bromide; residronate; ribavarin;
rimantadine hydrochloride; rotavirus vaccine; salmeterol xinafoate;
somatostatin; spectinomycin; stavudine; streptokinase; ticarcillin;
tiludronate; tissue type plasminogen activator TNFR:Fc; TNK-tPA;
trimetrexate gluconate; trospectinomycin; tumor necrosis factor;
typhoid vaccine live; urokinase; vancomycin; valacyclovir,
vasopressin and vasopressin derivatives; vinblastine; vincristine;
vinorelbine; warfarin sodium; zalcitabine; zanamivir; zidovudine;
pharmaceutically acceptable salts, isomers and derivatives thereof,
and mixtures thereof.
[0045] Most preferred hydrophilic active ingredients include
acamprosate, acarbose; alendronate; amantadine hydrochloride;
azithromycin; calcitonin human; calcitonin salmon; ceftriaxone;
cefuroxime axetil; chorionic gonadotropin; cromolyn sodium;
dalteparin sodium; danaparoid; desmopressin; didanosine; etidronate
disodium; enoxaparin sodium; epoetin alpha; factor IX; famciclovir;
foscarnet sodium; galantamine, ganciclovir; granulocyte colony
stimulating factor; granulocyte-macrophage stimulating factor;
recombinant human growth hormones; bovine growth hormone; glucagon;
gonadotropin releasing hormone and synthetic analogs thereof, GnRH;
gonadorelin; heparin sodium; indinavir sulfate; influenza virus
vaccine; interleukin-2; interleukin-3; insulin-human; insulin
lispro; insulin procine interferon alpha; interferon beta;
leuprolide acetate; metformin hydrochloride; nedocromil sodium;
neostigmine bromide; neostigmine methyl sulfate; neurontin;
nitrofurantoin, octreotide acetate; olpadronate; pamidronate
disodium; residronate; rimantadine hydrochloride; salmeterol
xinafoate; somatostatin; stavudine; ticarcillin; tiludronate;
tissue type plasminogen activator; TNFR:Fc; TNK-tPA; tumor necrosis
factor; typhoid vaccine live; vancomycin; valacyclovir; vasopressin
and vasopressin derivatives; zalcitabine; zanamivir; zidovudine;
pharmaceutically acceptable salts, isomers and derivatives thereof;
and mixtures thereof.
[0046] 2. Surfactants
[0047] Various embodiments of the invention, as described in more
detail below, include a hydrophilic surfactant. Hydrophilic
surfactants can be used to provide any of several advantageous
characteristics to the compositions, including: increased
solubility of the active ingredient in the solid carrier; improved
dissolution of the active ingredient; improved solubilization of
the active ingredient upon dissolution; enhanced absorption and/or
bioavailability of the active ingredient, particularly a
hydrophilic active ingredient; and improved stability, both
physical and chemical, of the active ingredient. The hydrophilic
surfactant can be a single hydrophilic surfactant or a mixture of
hydrophilic surfactants, and can be ionic or non-ionic.
[0048] Likewise, various embodiments of the invention include a
lipophilic component, which can be a lipophilic surfactant,
including a mixture of lipophilic surfactants, a triglyceride, or a
mixture thereof. The lipophilic surfactant can provide any of the
advantageous characteristics listed above for hydrophilic
surfactants, as well as further enhancing the function of the
surfactants. These various embodiments are described in more detail
below. For convenience, the surfactants are described in this
section, and the triglycerides in the section that follows.
[0049] As is well known in the art, the terms "hydrophilic" and
"lipophilic" are relative terms. To function as a surfactant, a
compound must necessarily include polar or charged hydrophilic
moieties as well as non-polar hydrophobic (lipophilic) moieties;
i.e., a surfactant compound must be amphiphilic. An empirical
parameter commonly used to characterize the relative hydrophilicity
and lipophilicity of non-ionic amphiphilic compounds is the
hydrophilic-lipophilic balance (the "HLB" value). Surfactants with
lower HLB values are more lipophilic, and have greater solubility
in oils, whereas surfactants with higher HLB values are more
hydrophilic, and have greater solubility in aqueous solutions.
[0050] Using HLB values as a rough guide, hydrophilic surfactants
are generally considered to be those compounds having an HLB value
greater than about 10, as well as anionic, cationic, or
zwitterionic compounds for which the HLB scale is not generally
applicable. Similarly, lipophilic surfactants are compounds having
an HLB value less than about 10.
[0051] It should be appreciated that the HLB value of a surfactant
is merely a rough guide generally used to enable formulation of
industrial, pharmaceutical and cosmetic emulsions. For many
important surfactants, including several polyethoxylated
surfactants, it has been reported that HLB values can differ by as
much as about 8 HLB units, depending upon the empirical method
chosen to determine the HLB value (Schott, J. Pharm. Sciences,
79(1), 87-88 (1990)). Likewise, for certain polypropylene oxide
containing block copolymers (poloxamers, available commercially as
PLURONIC.RTM. surfactants, BASF Corp.), the HLB values may not
accurately reflect the true physical chemical nature of the
compounds. Finally, commercial surfactant products are generally
not pure compounds, but are often complex mixtures of compounds,
and the HLB value reported for a particular compound may more
accurately be characteristic of the commercial product of which the
compound is a major component. Different commercial products having
the same primary surfactant component can, and typically do, have
different HLB values. In addition, a certain amount of lot-to-lot
variability is expected even for a single commercial surfactant
product. Keeping these inherent difficulties in mind, and using HLB
values as a guide, one skilled in the art can readily identify
surfactants having suitable hydrophilicity or lipophilicity for use
in the present invention, as described herein.
[0052] Surfactants can be any surfactant suitable for use in
pharmaceutical compositions. Suitable surfactants can be anionic,
cationic, zwitterionic or non-ionic. Such surfactants can be
grouped into the following general chemical classes detailed in the
Tables herein. The HLB values given in the Tables below generally
represent the HLB value as reported by the manufacturer of the
corresponding commercial product. In cases where more than one
commercial product is listed, the HLB value in the Tables is the
value as reported for one of the commercial products, a rough
average of the reported values, or a value that, in the judgment of
the present inventors, is more reliable.
[0053] It should be emphasized that the invention is not limited to
the surfactants in the Tables, which show representative, but not
exclusive, lists of available surfactants. In addition, refined,
distilled or fractionated surfactants, purified fractions thereof,
or re-esterified fractions, are also within the scope of the
invention, although not specifically listed in the Tables.
[0054] 2.1. Polyethoxylated Fatty Acids
[0055] Although polyethylene glycol (PEG) itself does not function
as a surfactant, a variety of PEG-fatty acid esters have useful
surfactant properties. Examples of polyethoxylated fatty acid
monoester surfactants commercially available are shown in Table
1.
TABLE-US-00001 TABLE 1 PEG-Fatty Acid Monoester Surfactants
COMPOUND COMMERCIAL PRODUCT (Supplier) HLB PEG 4-100 monolaurate
Crodet L series (Croda) >9 PEG 4-100 monooleate Crodet O series
(Croda) >8 PEG 4-100 monostearate Crodet S series (Croda), Myrj
Series (Atlas/ICI) >6 PEG 400 distearate Cithrol 4DS series
(Croda) >10 PEG 100, 200, 300 monolaurate Cithrol ML series
(Croda) >10 PEG 100, 200, 300 monooleate Cithrol MO series
(Croda) >10 PEG 400 dioleate Cithrol 4DO series (Croda) >10
PEG 400-1000 monostearate Cithrol MS series (Croda) >10 PEG-1
stearate Nikkol MYS-1EX (Nikko), Coster K1 (Condea) 2 PEG-2
stearate Nikkol MYS-2 (Nikko) 4 PEG-2 oleate Nikkol MYO-2 (Nikko)
4.5 PEG-4 laurate Mapeg .RTM. 200 ML (PPG), Kessco .RTM. PEG 200ML
(Stepan), 9.3 LIPOPEG 2L (Lipo Chem.) PEG-4 oleate Mapeg .RTM. 200
MO (PPG), Kessco .RTM. PEG200 MO (Stepan), 8.3 PEG-4 stearate
Kessco .RTM. PEG 200 MS (Stepan), Hodag 20 S (Calgene), 6.5 Nikkol
MYS-4 (Nikko) PEG-5 stearate Nikkol TMGS-5 (Nikko) 9.5 PEG-5 oleate
Nikkol TMGO-5 (Nikko) 9.5 PEG-6 oleate Algon OL 60 (Auschem SpA),
Kessco .RTM. PEG 300 MO 8.5 Stepan), Nikkol MYO-6 (Nikko),
Emulgante A6 (Condea) PEG-7 oleate Algon OL 70 (Auschem SpA) 10.4
PEG-6 laurate Kessco .RTM. PEG300 ML (Stepan) 11.4 PEG-7 laurate
Lauridac 7 (Condea) 13 PEG-6 stearate Kessco .RTM. PEG300 MS
(Stepan) 9.7 PEG-8 laurate Mapeg .RTM. 400 ML (PPG), LIPOPEG 4DL
(Lipo Chem.) 13 PEG-8 oleate Mapeg .RTM. 400 MO (PPG), Emulgante A8
(Condea) 12 PEG-8 stearate Mapeg .RTM. 400 MS (PPG), Myrj 45 12
PEG-9 oleate Emulgante A9 (Condea) >10 PEG-9 stearate Cremophor
S9 (BASF) >10 PEG-10 laurate Nikkol MYL-10 (Nikko), Lauridac 10
(Croda) 13 PEG-10 oleate Nikkol MYO-10 (Nikko) 11 PEG-10 stearate
Nikkol MYS-10 (Nikko), Coster K100 (Condea) 11 PEG-12 laurate
Kessco .RTM. PEG 600ML (Stepan) 15 PEG-12 oleate Kessco .RTM. PEG
600MO (Stepan) 14 PEG-12 ricinoleate (CAS # 9004-97-1) >10
PEG-12 stearate Mapeg .RTM. 600 MS (PPG), Kessco .RTM. PEG 600MS
(Stepan) 14 PEG-15 stearate Nikkol TMGS-15 (Nikko), Koster K15
(Condea) 14 PEG-15 oleate Nikkol TMGO-15 (Nikko) 15 PEG-20 laurate
Kessco .RTM. PEG 1000 ML (Stepan) 17 PEG-20 oleate Kessco .RTM. PEG
1000 MO (Stepan) 15 PEG-20 stearate Mapeg .RTM. 1000 MS (PPG),
Kessco .RTM. PEG 1000 MS Stepan), 16 Myrj 49 PEG-25 stearate Nikkol
MYS-25 (Nikko) 15 PEG-32 laurate Kessco .RTM. PEG 1540 ML (Stepan)
16 PEG-32 oleate Kessco .RTM. PEG 1540 MO (Stepan) 17 PEG-32
stearate Kessco .RTM. PEG 1540 MS (Stepan) 17 PEG-30 stearate Myrj
51 >10 PEG-40 laurate Crodet L40 (Croda) 17.9 PEG-40 oleate
Crodet O40 (Croda) 17.4 PEG-40 stearate Myrj 52, Emerest .RTM. 2715
(Henkel), Nikkol MYS-40 (Nikko) >10 PEG-45 stearate Nikkol
MYS-45 (Nikko) 18 PEG-50 stearate Myrj 53 >10 PEG-55 stearate
Nikkol MYS-55 (Nikko) 18 PEG-100 oleate Crodet O-100 (Croda) 18.8
PEG-100 stearate Myrj 59, Arlacel 165 (ICI) 19 PEG-200 oleate
Albunol 200 MO (Taiwan Surf.) >10 PEG-400 oleate LACTOMUL
(Henkel), Albunol 400 MO (Taiwan Surf.) >10 PEG-600 oleate
Albunol 600 MO (Taiwan Surf.) >10
[0056] 2.2 PEG-Fatty Acid Diesters
[0057] Polyethylene glycol (PEG) fatty acid diesters are also
suitable for use as surfactants in the compositions of the present
invention. Representative PEG-fatty acid diesters are shown in
Table 2.
TABLE-US-00002 TABLE 2 PEG-Fatty Acid Diester Surfactants COMPOUND
COMMERCIAL PRODUCT (Supplier) HLB PEG-4 dilaurate Mapeg .RTM. 200
DL (PPG), Kessco .RTM. PEG 200 DL (Stepan), 7 LIPOPEG 2-DL (Lipo
Chem.) PEG-4 dioleate Mapeg .RTM. 200 DO (PPG), 6 PEG-4 distearate
Kessco .RTM. 200 DS (Stepan) 5 PEG-6 dilaurate Kessco .RTM. PEG 300
DL (Stepan) 9.8 PEG-6 dioleate Kessco .RTM. PEG 300 DO (Stepan) 7.2
PEG-6 distearate Kessco .RTM. PEG 300 DS (Stepan) 6.5 PEG-8
dilaurate Mapeg .RTM. 400 DL (PPG), Kessco .RTM. PEG 400 DL
(Stepan), 11 LIPOPEG 4 DL (Lipo Chem.) PEG-8 dioleate Mapeg .RTM.
400 DO (PPG), Kessco .RTM. PEG 400 DO (Stepan), 8.8 LIPOPEG 4 O
(Lipo Chem.) PEG-8 distearate Mapeg .RTM. 400 DS (PPG), CDS 400
(Nikkol) 11 PEG-10 dipalmitate Polyaldo 2PKFG >10 PEG-12
dilaurate Kessco .RTM. PEG 600 DL (Stepan) 11.7 PEG-12 distearate
Kessco .RTM. PEG 600 DS (Stepan) 10.7 PEG-12 dioleate Mapeg .RTM.
600 DO (PPG), Kessco .RTM. 600 DO(Stepan) 10 PEG-20 dilaurate
Kessco .RTM. PEG 1000 DL (Stepan) 15 PEG-20 dioleate Kessco .RTM.
PEG 1000 DO (Stepan) 13 PEG-20 distearate Kessco .RTM. PEG 1000 DS
(Stepan) 12 PEG-32 dilaurate Kessco .RTM. PEG 1540 DL (Stepan) 16
PEG-32 dioleate Kessco .RTM. PEG 1540 DO (Stepan) 15 PEG-32
distearate Kessco .RTM. PEG 1540 DS (Stepan) 15 PEG-400 dioleate
Cithrol 4DO series (Croda) >10 PEG-400 distearate Cithrol 4DS
series (Croda) >10
[0058] 2.3 PEG-Fatty Acid Mono- and Di-Ester Mixtures
[0059] In general, mixtures of surfactants are also useful in the
present invention, including mixtures of two or more commercial
surfactant products. Several PEG-fatty acid esters are marketed
commercially as mixtures or mono- and diesters. Representative
surfactant mixtures are shown in Table 3.
TABLE-US-00003 TABLE 3 PEG-Fatty Acid Mono- and Diester Mixtures
COMPOUND COMMERCIAL PRODUCT (Supplier) PEG 4-150 mono, dilaurate
Kessco .RTM. PEG 200-6000 mono, dilaurate (Stepan) PEG 4-150 mono,
dioleate Kessco .RTM. PEG 200-6000 mono, dioleate (Stepan) PEG
4-150 mono, distearate Kessco .RTM. 200-6000 mono, distearate
(Stepan)
[0060] 2.4 Polyethylene Glycol Glycerol Fatty Acid Esters
[0061] Suitable PEG glycerol fatty acid esters are shown in Table
4.
TABLE-US-00004 TABLE 4 PEG Glycerol Fatty Acid Esters COMPOUND
COMMERCIAL PRODUCT (Supplier) HLB PEG-20 glyceryl laurate Tagat
.RTM. L (Goldschmidt) 16 PEG-30 glyceryl laurate Tagat .RTM. L2
(Goldschmidt) 16 PEG-15 glyceryl laurate Glycerox L series (Croda)
15 PEG-40 glyceryl laurate Glycerox L series (Croda) 15 PEG-20
glyceryl stearate Capmul .RTM. EMG (ABITEC), 13 Aldo .RTM. MS-20
KFG (Lonza) PEG-20 glyceryl oleate Tagat .RTM. O (Goldschmidt)
>10 PEG-30 glyceryl oleate Tagat .RTM. O2 (Goldschmidt)
>10
[0062] 2.5 Alcohol--Oil Transesterification Products
[0063] A large number of surfactants of different degrees of
lipophilicity or hydrophilicity can be prepared by reaction of
alcohols or polyalcohols with a variety of natural and/or
hydrogenated oils. Most commonly, the oils used are castor oil or
hydrogenated castor oil, or an edible vegetable oil such as corn
oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil, or
almond oil. Preferred alcohols include glycerol, propylene glycol,
ethylene glycol, polyethylene glycol, sorbitol, and
pentaerythritol. Representative surfactants of this class suitable
for use in the present invention are shown in Table 5.
TABLE-US-00005 TABLE 5 Transesterification Products of Oils and
Alcohols COMPOUND COMMERCIAL PRODUCT (Supplier) HLB PEG-3 castor
oil Nikkol CO-3 (Nikko) 3 PEG-5, 9, and 16 castor oil ACCONON CA
series (ABITEC) 6-7 PEG-20 castor oil Emalex C-20 (Nihon Emulsion),
Nikkol CO-20 TX 11 (Nikko) PEG-23 castor oil Emulgante EL23 >10
PEG-30 castor oil Emalex C-30 (Nihon Emulsion), Alkamuls .RTM. EL
620 11 (Rhone-Poulenc), Incrocas 30 (Croda) PEG-35 castor oil
Cremophor EL and EL-P (BASF), Emulphor EL, Incrocas-35 (Croda),
Emulgin RO 35 (Henkel) PEG-38 castor oil Emulgante EL 65 (Condea)
PEG-40 castor oil Emalex C-40 (Nihon Emulsion), Alkamuls .RTM. EL
719 13 (Rhone-Poulenc) PEG-50 castor oil Emalex C-50 (Nihon
Emulsion) 14 PEG-56 castor oil Eumulgin .RTM. PRT 56 (Pulcra SA)
>10 PEG-60 castor oil Nikkol CO-60TX (Nikko) 14 PEG-100 castor
oil Thornley >10 PEG-200 castor oil Eumulgin .RTM. PRT 200
(Pulcra SA) >10 PEG-5 hydrogenated castor oil Nikkol HCO-5
(Nikko) 6 PEG-7 hydrogenated castor oil Simusol .RTM. 989 (Seppic),
Cremophor WO7 (BASF) 6 PEG-10 hydrogenated castor oil Nikkol HCO-10
(Nikko) 6.5 PEG-20 hydrogenated castor oil Nikkol HCO-20 (Nikko) 11
PEG-25 hydrogenated castor oil Simulsol .RTM. 1292 (Seppic), Cerex
ELS 250 (Auschem 11 SpA) PEG-30 hydrogenated castor oil Nikkol
HCO-30 (Nikko) 11 PEG-40 hydrogenated castor oil Cremophor RH 40
(BASF), Croduret (Croda), 13 Emulgin HRE (Henkel) PEG-45
hydrogenated castor oil Cerex ELS 450 (Auschem Spa) 14 PEG-50
hydrogenated castor oil Emalex HC-50 (Nihon Emulsion) 14 PEG-60
hydrogenated castor oil Nikkol HCO-60 (Nikko); Cremophor RH 60
(BASF) 15 PEG-80 hydrogenated castor oil Nikkol HCO-80 (Nikko) 15
PEG-100 hydrogenated castor oil Nikkol HCO-100 (Nikko) 17 PEG-6
corn oil Labrafil .RTM. M 2125 CS (Gattefosse) 4 PEG-6 almond oil
Labrafil .RTM. M 1966 CS (Gattefosse) 4 PEG-6 apricot kernel oil
Labrafil .RTM. M 1944 CS (Gattefosse) 4 PEG-6 olive oil Labrafil
.RTM. M 1980 CS (Gattefosse) 4 PEG-6 peanut oil Labrafil .RTM. M
1969 CS (Gattefosse) 4 PEG-6 hydrogenated palm kernel Labrafil
.RTM. M 2130 BS (Gattefosse) 4 oil PEG-6 palm kernel oil Labrafil
.RTM. M 2130 CS (Gattefosse) 4 PEG-6 triolein Labrafil .RTM. M 2735
CS (Gattefosse) 4 PEG-8 corn oil Labrafil .RTM. WL 2609 BS
(Gattefosse) 6-7 PEG-20 corn glycerides Crovol M40 (Croda) 10
PEG-20 almond glycerides Crovol A40 (Croda) 10 PEG-25 trioleate
TAGAT .RTM. TO (Goldschmidt) 11 PEG-40 palm kernel oil Crovol PK-70
>10 PEG-60 corn glycerides Crovol M70(Croda) 15 PEG-60 almond
glycerides Crovol A70 (Croda) 15 PEG-4 caprylic/capric triglyceride
Labrafac .RTM. Hydro (Gattefosse), 4-5 PEG-8 caprylic/capric
glycerides Labrasol (Gattefosse), Labrafac CM 10 (Gattefosse)
>10 PEG-6 caprylic/capric glycerides SOFTIGEN .RTM. 767 (Huls),
Glycerox 767 (Croda) 19 Lauroyl macrogol-32 glyceride GELUCIRE
44/14 (Gattefosse) 14 Stearoyl macrogol glyceride GELUCIRE 50/13
(Gattefosse) 13 Mono, di, tri, tetra esters of SorbitoGlyceride
(Gattefosse) <10 vegetable oils and sorbitol Pentaerythrityl
tetraisostearate Crodamol PTIS (Croda) <10 Pentaerythrityl
distearate Albunol DS (Taiwan Surf.) <10 Pentaerythrityl
tetraoleate Liponate PO-4 (Lipo Chem.) <10 Pentaerythrityl
tetrastearate Liponate PS-4 (Lipo Chem.) <10 Pentaerythrityl
Liponate PE-810 (Lipo Chem.), Crodamol PTC <10
tetracaprylate/tetracaprate (Croda) Pentaerythrityl tetraoctanoate
Nikkol Pentarate 408 (Nikko)
[0064] 2.6. Polyglycerized Fatty Acids
[0065] Polyglycerol esters of fatty acids are also suitable
surfactants for the present invention. Examples of suitable
polyglyceryl esters are shown in Table 6.
TABLE-US-00006 TABLE 6 Polyglycerized Fatty Acids COMPOUND
COMMERCIAL PRODUCT (Supplier) HLB Polyglyceryl-2 stearate Nikkol
DGMS (Nikko) 5-7 Polyglyceryl-2 oleate Nikkol DGMO (Nikko) 5-7
Polyglyceryl-2 isostearate Nikkol DGMIS (Nikko) 5-7 Polyglyceryl-3
oleate Caprol .RTM. 3GO (ABITEC), Drewpol 3-1-O (Stepan) 6.5
Polyglyceryl-4 oleate Nikkol Tetraglyn 1-O (Nikko) 5-7
Polyglyceryl-4 stearate Nikkol Tetraglyn 1-S (Nikko) 5-6
Polyglyceryl-6 oleate Drewpol 6-1-O (Stepan), Nikkol Hexaglyn 1-O
(Nikko) 9 Polyglyceryl-10 laurate Nikkol Decaglyn 1-L (Nikko) 15
Polyglyceryl-10 oleate Nikkol Decaglyn 1-O (Nikko) 14
Polyglyceryl-10 stearate Nikkol Decaglyn 1-S (Nikko) 12
Polyglyceryl-6 ricinoleate Nikkol Hexaglyn PR-15 (Nikko) >8
Polyglyceryl-10 linoleate Nikkol Decaglyn 1-LN (Nikko) 12
Polyglyceryl-6 pentaoleate Nikkol Hexaglyn 5-O (Nikko) <10
Polyglyceryl-3 dioleate Cremophor GO32 (BASF) <10 Polyglyceryl-3
distearate Cremophor GS32 (BASF) <10 Polyglyceryl-4 pentaoleate
Nikkol Tetraglyn 5-O (Nikko) <10 Polyglyceryl-6 dioleate Caprol
.RTM. 6G20 (ABITEC); Hodag PGO-62 (Calgene), 8.5 PLUROL OLEIQUE CC
497 (Gattefosse) Polyglyceryl-2 dioleate Nikkol DGDO (Nikko) 7
Polyglyceryl-10 trioleate Nikkol Decaglyn 3-O (Nikko) 7
Polyglyceryl-10 pentaoleate Nikkol Decaglyn 5-O (Nikko) 3.5
Polyglyceryl-10 septaoleate Nikkol Decaglyn 7-O (Nikko) 3
Polyglyceryl-10 tetraoleate Caprol .RTM. 10G4O (ABITEC); Hodag
PGO-62 (CALGENE), 6.2 Drewpol 10-4-O (Stepan) Polyglyceryl-10
Nikkol Decaglyn 10-IS (Nikko) <10 decaisostearate
Polyglyceryl-101 decaoleate Drewpol 10-10-O (Stepan), Caprol 10G10O
(ABITEC), 3.5 Nikkol Decaglyn 10-O Polyglyceryl-10 mono, dioleate
Caprol .RTM. PGE 860 (ABITEC) 11 Polyglyceryl polyricinoleate
Polymuls (Henkel) 3-20
[0066] 2.7. Propylene Glycol Fatty Acid Esters
[0067] Esters of propylene glycol and fatty acids are suitable
surfactants for use in the present invention. Examples of
surfactants of this class are given in Table 7.
TABLE-US-00007 TABLE 7 Propylene Glycol Fatty Acid Esters COMPOUND
COMMERCIAL PRODUCT (Supplier) HLB Propylene glycol Capryol 90
(Gattefosse), Nikkol Sefsol 218 (Nikko) <10 monocaprylate
Propylene glycol Lauroglycol 90 (Gattefosse), Lauroglycol FCC
(Gattefosse) <10 monolaurate Propylene glycol oleate Lutrol
OP2000 (BASF) <10 Propylene glycol myristate Mirpyl <10
Propylene glycol ADM PGME-03 (ADM), LIPO PGMS (Lipo Chem.), Aldo
.RTM. 3-4 monostearate PGHMS (Lonza) Propylene glycol hydroxy
<10 stearate Propylene glycol ricinoleate PROPYMULS (Henkel)
<10 Propylene glycol isostearate <10 Propylene glycol
monooleate Myverol P-O6 (Eastman) <10 Propylene glycol Captex
.RTM. 200 (ABITEC), Miglyol .RTM. 840 (Huls), Neobee .RTM. M- >6
dicaprylate/dicaprate 20 (Stepan) Propylene glycol dioctanoate
Captex .RTM. 800 (ABITEC) >6 Propylene glycol LABRAFAC PG
(Gattefosse) >6 caprylate/caprate Propylene glycol dilaurate
>6 Propylene glycol distearate Kessco .RTM. PGDS (Stepan) >6
Propylene glycol dicaprylate Nikkol Sefsol 228 (Nikko) >6
Propylene glycol dicaprate Nikkol PDD (Nikko) >6
[0068] 2.8. Mixtures of Propylene Glycol Esters--Glycerol
Esters
[0069] In general, mixtures of surfactants are also suitable for
use in the present invention. In particular, mixtures of propylene
glycol fatty acid esters and glycerol fatty acid esters are
suitable and are commercially available. Examples of these
surfactants are shown in Table 8.
TABLE-US-00008 TABLE 8 Glycerol/Propylene Glycol Fatty Acid Esters
COMPOUND COMMERCIAL PRODUCT (Supplier) HLB Oleic ATMOS 300, ARLACEL
186 (ICI) 3-4 Stearic ATMOS 150 3-4
[0070] 2.9. Mono- and Diglycerides
[0071] A particularly important class of surfactants is the class
of mono- and diglycerides. These surfactants are generally
lipophilic. Examples of these surfactants are given in Table 9.
TABLE-US-00009 TABLE 9 Mono- and Diglyceride Surfactants COMPOUND
COMMERCIAL PRODUCT (Supplier) HLB Monopalmitolein (C16:1) (Larodan)
<10 Monoelaidin (C18:1) (Larodan) <10 Monocaproin (C6)
(Larodan) <10 Monocaprylin (Larodan) <10 Monocaprin (Larodan)
<10 Monolaurin (Larodan) <10 Glyceryl monomyristate Nikkol
MGM (Nikko) 3-4 (C14) Glyceryl monooleate (C18:1) PECEOL
(Gattefosse), Hodag GMO-D, Nikkol MGO 3-4 (Nikko) Glyceryl
monooleate RYLO series (Danisco), DIMODAN series (Danisco), 3-4
EMULDAN (Danisco), ALDO .RTM. MO FG (Lonza), Kessco GMO (Stepan),
MONOMULS .RTM. series (Henkel), TEGIN O, DREWMULSE GMO (Stepan),
Atlas G-695 (ICI), GMOrphic 80 (Eastman), ADM DMG-40, 70, and 100
(ADM), Myverol (Eastman) Glycerol OLICINE (Gattefosse) 3-4
monooleate/linoleate Glycerol monolinoleate Maisine (Gattefosse),
Myverol 18-92, Myverol 18-06 3-4 (Eastman) Glyceryl ricinoleate
Softigen .RTM. 701 (Huls), HODAG GMR-D (Calgene), 6 ALDO .RTM. MR
(Lonza) Glyceryl monolaurate ALDO .RTM. MLD (Lonza), Hodag GML
(Calgene) 6.8 Glycerol monopalmitate Emalex GMS-P (Nihon) 4
Glycerol monostearate Capmul .RTM. GMS (ABITEC), Myvaplex
(Eastman), Imwitor .RTM. 5-9 191 (Huls), CUTINA .RTM. GMS, Aldo
.RTM. MS (Lonza), Nikkol MGS series (Nikko) Glyceryl mono- and
di-oleate Capmul .RTM. GMO-K (ABITEC) <10 Glyceryl
palmitic/stearic CUTINA MD-A, ESTAGEL-G18 <10 Glyceryl acetate
Lamegin .RTM. EE (Grunau GmbH) <10 Glyceryl laurate Imwitor
.RTM. 312 (Huls), Monomuls .RTM. 90-45 (Grunau GmbH), 4 Aldo .RTM.
MLD (Lonza) Glyceryl Imwitor .RTM. 375 (Huls) <10
citrate/lactate/oleate/ linoleate Glyceryl caprylate Imwitor .RTM.
308 (Huls), Capmul .RTM. MCMC8 (ABITEC) 5-6 Glyceryl
caprylate/caprate Capmul .RTM. MCM (ABITEC) 5-6 Caprylic acid
Imwitor .RTM. 988 (Huls) 5-6 mono/diglycerides Caprylic/capric
glycerides Imwitor .RTM. 742 (Huls) <10 Mono-and diacetylated
Myvacet .RTM. 9-45, Myvacet .RTM. 9-40, Myvacet .RTM. 9-08 3.8-4
monoglycerides (Eastman), Lamegin .RTM. (Grunau) Glyceryl
monostearate Aldo .RTM. MS, Arlacel 129 (ICI), LIPO GMS (Lipo
Chem.), 4.4 Imwitor .RTM. 191 (Huls), Myvaplex (Eastman) Lactic
acid esters of mono- LAMEGIN GLP (Henkel) <10 and di-glycerides
Dicaproin (C6) (Larodan) <10 Dicaprin (C10) (Larodan) <10
Dioctanoin (C8) (Larodan) <10 Dimyristin (C14) (Larodan) <10
Dipalmitin (C16) (Larodan) <10 Distearin (Larodan) <10
Glyceryl dilaurate (C12) Capmul .RTM. GDL (ABITEC) 3-4 Glyceryl
dioleate Capmul .RTM. GDO (ABITEC) 3-4 Glycerol esters of fatty
acids GELUCIRE 39/01 (Gattefosse), GELUCIRE 43/01 1 (Gattefosse)
GELUCIRE 37/06 (Gattefosse) 6 Dipalmitolein (C16:1) (Larodan)
<10 1,2 and 1,3-diolein (C18:1) (Larodan) <10 Dielaidin
(C18:1) (Larodan) <10 Dilinolein (C18:2) (Larodan) <10
[0072] 2.10. Sterol and Sterol Derivatives
[0073] Sterols and derivatives of sterols are suitable surfactants
for use in the present invention. These surfactants can be
hydrophilic or lipophilic. Examples of surfactants of this class
are shown in Table 10.
TABLE-US-00010 TABLE 10 Sterol and Sterol Derivative Surfactants
COMPOUND COMMERCIAL PRODUCT (Supplier) HLB Cholesterol, sitosterol,
<10 lanosterol PEG-24 cholesterol ether Solulan C-24 (Amerchol)
>10 PEG-30 cholestanol Nikkol DHC (Nikko) >10 Phytosterol
GENEROL series (Henkel) <10 PEG-25 phyto sterol Nikkol BPSH-25
(Nikko) >10 PEG-5 soya sterol Nikkol BPS-5 (Nikko) <10 PEG-10
soya sterol Nikkol BPS-10 (Nikko) <10 PEG-20 soya sterol Nikkol
BPS-20 (Nikko) <10 PEG-30 soya sterol Nikkol BPS-30 (Nikko)
>10
[0074] 2.11. Polyethylene Glycol Sorbitan Fatty Acid Esters
[0075] A variety of PEG-sorbitan fatty acid esters are available
and are suitable for use as surfactants in the present invention.
In general, these surfactants are hydrophilic, although several
lipophilic surfactants of this class can be used. Examples of these
surfactants are shown in Table 11.
TABLE-US-00011 TABLE 11 PEG-Sorbitan Fatty Acid Esters COMPOUND
COMMERCIAL PRODUCT (Supplier) HLB PEG-10 sorbitan laurate Liposorb
L-10 (Lipo Chem.) >10 PEG-20 sorbitan monolaurate Tween-20
(Atlas/ICI), Crillet 1 (Croda), DACOL MLS 20 17 (Condea) PEG-4
sorbitan monolaurate Tween-21 (Atlas/ICI), Crillet 11 (Croda) 13
PEG-80 sorbitan monolaurate Hodag PSML-80 (Calgene); T-Maz 28
>10 PEG-6 sorbitan monolaurate Nikkol GL-1 (Nikko) 16 PEG-20
sorbitan monopalmitate Tween-40 (Atlas/ICI), Crillet 2 (Croda) 16
PEG-20 sorbitan monostearate Tween-60 (Atlas/ICI), Crillet 3
(Croda) 15 PEG-4 sorbitan monostearate Tween-61 (Atlas/ICI),
Crillet 31 (Croda) 9.6 PEG-8 sorbitan monostearate DACOL MSS
(Condea) >10 PEG-6 sorbitan monostearate Nikkol TS106 (Nikko) 11
PEG-20 sorbitan tristearate Tween-65 (Atlas/ICI), Crillet 35
(Croda) 11 PEG-6 sorbitan tetrastearate Nikkol GS-6 (Nikko) 3
PEG-60 sorbitan tetrastearate Nikkol GS-460 (Nikko) 13 PEG-5
sorbitan monooleate Tween-81 (Atlas/ICI), Crillet 41 (Croda) 10
PEG-6 sorbitan monooleate Nikkol TO-106 (Nikko) 10 PEG-20 sorbitan
monooleate Tween-80 (Atlas/ICI), Crillet 4 (Croda) 15 PEG-40
sorbitan oleate Emalex ET 8040 (Nihon Emulsion) 18 PEG-20 sorbitan
trioleate Tween-85 (Atlas/ICI), Crillet 45 (Croda) 11 PEG-6
sorbitan tetraoleate Nikkol GO-4 (Nikko) 8.5 PEG-30 sorbitan
tetraoleate Nikkol GO-430 (Nikko) 12 PEG-40 sorbitan tetraoleate
Nikkol GO-440 (Nikko) 13 PEG-20 sorbitan Tween-120 (Atlas/ICI),
Crillet 6 (Croda) >10 monoisostearate PEG sorbitol hexaoleate
Atlas G-1086 (ICI) 10 PEG-6 sorbitol hexastearate Nikkol GS-6
(Nikko) 3
[0076] 2.12. Polyethylene Glycol Alkyl Ethers
[0077] Ethers of polyethylene glycol and alkyl alcohols are
suitable surfactants for use in the present invention. Examples of
these surfactants are shown in Table 12.
TABLE-US-00012 TABLE 12 Polyethylene Glycol Alkyl Ethers COMMERCIAL
PRODUCT COMPOUND (Supplier) HLB PEG-2 oleyl ether, oleth-2 Brij
92/93 (Atlas/ICI) 4.9 PEG-3 oleyl ether, oleth-3 Volpo 3 (Croda)
<10 PEG-5 oleyl ether, oleth-5 Volpo 5 (Croda) <10 PEG-10
oleyl ether, oleth-10 Volpo 10 (Croda), 12 Brij 96/97 (Atlas/ICI)
PEG-20 oleyl ether, oleth-20 Volpo 20 (Croda), 15 Brij 98/99
(Atlas/ICI) PEG-4 lauryl ether, laureth-4 Brij 30 (Atlas/ICI) 9.7
PEG-9 lauryl ether >10 PEG-23 lauryl ether, laureth-23 Brij 35
(Atlas/ICI) 17 PEG-2 cetyl ether Brij 52 (ICI) 5.3 PEG-10 cetyl
ether Brij 56 (ICI) 13 PEG-20 cetyl ether Brij 58 (ICI) 16 PEG-2
stearyl ether Brij 72 (ICI) 4.9 PEG-10 stearyl ether Brij 76 (ICI)
12 PEG-20 stearyl ether Brij 78 (ICI) 15 PEG-100 stearyl ether Brij
700 (ICI) >10
[0078] 2.13. Sugar Esters
[0079] Esters of sugars are suitable surfactants for use in the
present invention. Examples of such surfactants are shown in Table
13.
TABLE-US-00013 TABLE 13 Sugar Ester Surfactants COMPOUND COMMERCIAL
PRODUCT (Supplier) HLB Sucrose distearate SUCRO ESTER 7
(Gattefosse), 3 Crodesta F-10 (Croda) Sucrose SUCRO ESTER 11
(Gattefosse), 12 distearate/monostearate Crodesta F-110 (Croda)
Sucrose dipalmitate 7.4 Sucrose monostearate Crodesta F-160 (Croda)
15 Sucrose monopalmitate SUCRO ESTER 15 (Gattefosse) >10 Sucrose
monolaurate Saccharose monolaurate 15 1695 (Mitsubishi-Kasei)
[0080] 2.14. Polyethylene Glycol Alkyl Phenols
[0081] Several hydrophilic PEG-alkyl phenol surfactants are
available, and are suitable for use in the present invention.
Examples of these surfactants are shown in Table 14.
TABLE-US-00014 TABLE 14 Polyethylene Glycol Alkyl Phenol
Surfactants COMMERCIAL PRODUCT COMPOUND (Supplier) HLB PEG-10-100
nonyl phenol Triton X series (Rohm & Haas), >10 Igepal CA
series (GAF, USA), Antarox CA series (GAF, UK) PEG-15-100 octyl
phenol ether Triton N-series (Rohm & Haas), >10 Igepal CO
series (GAF, USA), Antarox CO series (GAF, UK)
[0082] 2.15. Polyoxyethylene-Polyoxypropylene Block Copolymers
[0083] The POE-POP block copolymers are a unique class of polymeric
surfactants. The unique structure of the surfactants, with
hydrophilic POE and lipophilic POP moieties in well-defined ratios
and positions, provides a wide variety of surfactants suitable for
use in the present invention. These surfactants are available under
various trade names, including Synperonic PE series (ICI);
Pluronic.RTM. series (BASF), Emkalyx, Lutrol (BASF), Supronic,
Monolan, Pluracare, and Plurodac. The generic term for these
polymers is "poloxamer" (CAS 9003-11-6). These polymers have the
formula:
HO(C.sub.2H.sub.4O).sub.a(C.sub.3H.sub.6O).sub.b(C.sub.2H.sub.4O).sub.aH
where "a" and "b" denote the number of polyoxyethylene and
polyoxypropylene units, respectively.
[0084] Examples of suitable surfactants of this class are shown in
Table 15. Since the compounds are widely available, commercial
sources are not listed in the Table. The compounds are listed by
generic name, with the corresponding "a" and "b" values.
TABLE-US-00015 TABLE 15 POE-POP Block Copolymers COMPOUND a, b
values in
HO(C.sub.2H.sub.4O).sub.a(C.sub.3H.sub.6O).sub.b(C.sub.2H.sub.4O).sub.aH
HLB Poloxamer 105 a = 11 b = 16 8 Poloxamer 108 a = 46 b = 16
>10 Poloxamer 122 a = 5 b = 21 3 Poloxamer 123 a = 7 b = 21 7
Poloxamer 124 a = 11 b = 21 >7 Poloxamer 181 a = 3 b = 30
Poloxamer 182 a = 8 b = 30 2 Poloxamer 183 a = 10 b = 30 Poloxamer
184 a = 13 b = 30 Poloxamer 185 a = 19 b = 30 Poloxamer 188 a = 75
b = 30 29 Poloxamer 212 a = 8 b = 35 Poloxamer 215 a = 24 b = 35
Poloxamer 217 a = 52 b = 35 Poloxamer 231 a = 16 b = 39 Poloxamer
234 a = 22 b = 39 Poloxamer 235 a = 27 b = 39 Poloxamer 237 a = 62
b = 39 24 Poloxamer 238 a = 97 b = 39 Poloxamer 282 a = 10 b = 47
Poloxamer 284 a = 21 b = 47 Poloxamer 288 a = 122 b = 47 >10
Poloxamer 331 a = 7 b = 54 0.5 Poloxamer 333 a = 20 b = 54
Poloxamer 334 a = 31 b = 54 Poloxamer 335 a = 38 b = 54 Poloxamer
338 a = 128 b = 54 Poloxamer 401 a = 6 b = 67 Poloxamer 402 a = 13
b = 67 Poloxamer 403 a = 21 b = 67 Poloxamer 407 a = 98 b = 67
[0085] 2.16. Sorbitan Fatty Acid Esters
[0086] Sorbitan esters of fatty acids are suitable surfactants for
use in the present invention. Examples of these surfactants are
shown in Table 16.
TABLE-US-00016 TABLE 16 Sorbitan Fatty Acid Ester Surfactants
COMPOUND COMMERCIAL PRODUCT (Supplier) HLB Sorbitan monolaurate
Span-20 (Atlas/ICI), Crill 1 (Croda), 8.6 Arlacel 20 (ICI) Sorbitan
monopalmitate Span-40 (Atlas/ICI), Crill 2 (Croda), 6.7 Nikkol
SP-10 (Nikko) Sorbitan monooleate Span-80 (Atlas/ICI), Crill 4
(Croda), 4.3 Crill 50 (Croda) Sorbitan monostearate Span-60
(Atlas/ICI), Crill 3 (Croda), 4.7 Nikkol SS-10 (Nikko) Sorbitan
trioleate Span-85 (Atlas/ICI), Crill 45 (Croda), 4.3 Nikkol SO-30
(Nikko) Sorbitan sesquioleate Arlacel-C (ICI), Crill 43 (Croda),
3.7 Nikkol SO-15 (Nikko) Sorbitan tristearate Span-65 (Atlas/ICI)
Crill 35 (Croda), 2.1 Nikkol SS-30 (Nikko) Sorbitan monoisostearate
Crill 6 (Croda), Nikkol SI-10 (Nikko) 4.7 Sorbitan sesquistearate
Nikkol SS-15 (Nikko) 4.2
[0087] 2.17. Lower Alcohol Fatty Acid Esters
[0088] Esters of lower alcohols (C.sub.4 to C.sub.4) and fatty
acids (C.sub.8 to C.sub.18) are suitable surfactants for use in the
present invention. Examples of these surfactants are shown in Table
17.
TABLE-US-00017 TABLE 17 Lower Alcohol Fatty Acid Ester Surfactants
COMPOUND COMMERCIAL PRODUCT (Supplier) HLB Ethyl oleate Crodamol EO
(Croda), Nikkol EOO (Nikko) <10 Isopropyl myristate Crodamol IPM
(Croda) <10 Isopropyl palmitate Crodamol IPP (Croda) <10
Ethyl linoleate Nikkol VF-E (Nikko) <10 Isopropyl linoleate
Nikkol VF-IP (Nikko) <10
[0089] 2.18. Ionic Surfactants
[0090] Ionic surfactants, including cationic, anionic and
zwitterionic surfactants, are suitable hydrophilic surfactants for
use in the present invention. Preferred anionic surfactants include
fatty acid salts and bile salts. Preferred cationic surfactants
include carnitines. Specifically, preferred ionic surfactants
include sodium oleate, sodium lauryl sulfate, sodium lauryl
sarcosinate, sodium dioctyl sulfosuccinate, sodium cholate, sodium
taurocholate; lauroyl carnitine; palmitoyl carnitine; and myristoyl
carnitine. Examples of such surfactants are shown in Table 18. For
simplicity, typical counterions are shown in the entries in the
Table. It will be appreciated by one skilled in the art, however,
that any bioacceptable counterion may be used. For example,
although the fatty acids are shown as sodium salts, other cation
counterions can also be used, such as alkali metal cations or
ammonium. Unlike typical non-ionic surfactants, these ionic
surfactants are generally available as pure compounds, rather than
commercial (proprietary) mixtures. Because these compounds are
readily available from a variety of commercial suppliers, such as
Aldrich, Sigma, and the like, commercial sources are not generally
listed in the Table.
TABLE-US-00018 TABLE 18 Ionic Surfactants COMPOUND HLB FATTY ACID
SALTS >10 Sodium caproate Sodium caprylate Sodium caprate Sodium
laurate Sodium myristate Sodium myristolate Sodium palmitate Sodium
palmitoleate Sodium oleate 18 Sodium ricinoleate Sodium linoleate
Sodium linolenate Sodium stearate Sodium lauryl sulfate (dodecyl)
40 Sodium tetradecyl sulfate Sodium lauryl sarcosinate Sodium
dioctyl sulfosuccinate [sodium docusate (Cytec)] BILE SALTS >10
Sodium cholate Sodium taurocholate Sodium glycocholate Sodium
deoxycholate Sodium taurodeoxycholate Sodium glycodeoxycholate
Sodium ursodeoxycholate Sodium chenodeoxycholate Sodium
taurochenodeoxycholate Sodium glyco chenodeoxycholate Sodium
cholylsarcosinate Sodium N-methyl taurocholate PHOSPHOLIPIDS
Egg/Soy lecithin [Epikuron .RTM. (Lucas Meyer), Ovothin .RTM.
(Lucas Meyer)] Cardiolipin Sphingomyelin Phosphatidylcholine
Phosphatidyl ethanolamine Phosphatidic acid Phosphatidyl glycerol
Phosphatidyl serine PHOSPHORIC ACID ESTERS Diethanolammonium
polyoxyethylene-10 oleyl ether phosphate Esterification products of
fatty alcohols or fatty alcohol ethoxylates with phosphoric acid or
anhydride CARBOXYLATES Ether carboxylates (by oxidation of terminal
OH group of fatty alcohol ethoxylates) Succinylated monoglycerides
[LAMEGIN ZE (Henkel)] Sodium stearyl fumarate Stearoyl propylene
glycol hydrogen succinate Mono/diacetylated tartaric acid esters of
mono- and diglycerides Citric acid esters of mono-, diglycerides
Glyceryl-lacto esters of fatty acids (CFR ref. 172.852) Acyl
lactylates: lactylic esters of fatty acids calcium/sodium
stearoyl-2-lactylate calcium/sodium stearoyl lactylate Alginate
salts Propylene glycol alginate SULFATES AND SULFONATES Ethoxylated
alkyl sulfates Alkyl benzene sulfones .alpha.-olefin sulfonates
Acyl isethionates Acyl taurates Alkyl glyceryl ether sulfonates
Octyl sulfosuccinate disodium Disodium
undecylenamideo-MEA-sulfosuccinate CATIONIC SURFACTANTS >10
Hexadecyl triammonium bromide Dodecyl ammonium chloride Alkyl
benzyldimethylammonium salts Diisobutyl phenoxyethoxydimethyl
benzylammonium salts Alkylpyridinium salts Betaines
(trialkylglycine): Lauryl betaine (N-lauryl,N,N-dimethylglycine)
Ethoxylated amines: Polyoxyethylene-15 coconut amine
[0091] 2.19 Unionized Ionizable Surfactants
[0092] Ionizable surfactants, when present in their unionized
(neutral, non-salt) form, are lipophilic surfactants suitable for
use in the compositions of the present invention. Particular
examples of such surfactants include free fatty acids, particularly
C.sub.6-22 fatty acids, and bile acids. More specifically, suitable
unionized ionizable surfactants include the free fatty acid and
bile acid forms of any of the fatty acid salts and bile salts shown
in Table 18.
[0093] 2.20 Derivatives of Fat-Soluble Vitamins
[0094] Derivatives of oil-soluble vitamins, such as vitamins A, D,
E, K, etc., are also useful surfactants for the compositions of the
present invention. An example of such a derivative is tocopheryl
PEG-1000 succinate (TPGS, available from Eastman).
[0095] 2.21 Preferred Surfactants
[0096] Among the above-listed surfactants, several combinations are
preferred. In general, surfactants or mixtures of surfactants that
solidify at ambient room temperature are most preferred. Also
preferred are surfactants or mixtures of surfactants that solidify
at ambient room temperature in combination with particular
lipophilic components, such as triglycerides, or with addition of
appropriate additives, such as viscosity modifiers, binders,
thickeners, and the like.
[0097] Preferred non-ionic hydrophilic surfactants include
alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl
macrogolglycerides; polyoxyethylene alkyl ethers; polyoxyethylene
alkylphenols; polyethylene glycol fatty acids esters; polyethylene
glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty
acid esters; polyoxyethylene-polyoxypropylene block copolymers;
polyglycerol fatty acid esters; polyoxyethylene glycerides;
polyoxyethylene sterols, derivatives, and analogues thereof;
polyoxyethylene vegetable oils; polyoxyethylene hydrogenated
vegetable oils; reaction mixtures of polyols with fatty acids,
glycerides, vegetable oils, hydrogenated vegetable oils, and
sterols; sugar esters; sugar ethers; sucroglycerides;
polyethoxylated fat-soluble vitamins or derivatives; and mixtures
thereof.
[0098] More preferably, the non-ionic hydrophilic surfactant is
selected from the group consisting of polyoxyethylene alkylethers;
polyethylene glycol fatty acid esters; polyethylene glycol glycerol
fatty acid esters; polyoxyethylene sorbitan fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; polyglyceryl
fatty acid esters; polyoxyethylene glycerides; polyoxyethylene
vegetable oils; and polyoxyethylene hydrogenated vegetable oils.
The glyceride can be a monoglyceride, diglyceride, triglyceride, or
a mixture.
[0099] Also preferred are non-ionic hydrophilic surfactants that
are reaction mixtures of polyols and fatty acids, glycerides,
vegetable oils, hydrogenated vegetable oils, or sterols. These
reaction mixtures are largely composed of the transesterification
products of the reaction, along with complex mixtures of other
reaction products. The polyol is preferably glycerol, ethylene
glycol, polyethylene glycol, sorbitol, propylene glycol,
pentaerythritol, or a saccharide.
[0100] The hydrophilic surfactant can also be, or can include as a
component, an ionic surfactant. Preferred ionic surfactants include
alkyl ammonium salts; bile acids and salts, analogues, and
derivatives thereof; fusidic acid and derivatives thereof; fatty
acid derivatives of amino acids, oligopeptides, and polypeptides;
glyceride derivatives of amino acids oligopeptides, and
polypeptides; acyl lactylates; mono- and di-acetylated tartaric
acid esters of mono- and di-glycerides; succinylated
monoglycerides; citric acid esters of mono- and di-glycerides;
alginate salts; propylene glycol alginate; lecithins and
hydrogenated lecithins; lysolecithin and hydrogenated
lysolecithins; lysophospholipids and derivatives thereof;
phospholipids and derivatives thereof; salts of alkylsulfates;
salts of fatty acids; sodium docusate; carnitines; and mixtures
thereof.
[0101] More preferable ionic surfactants include bile acids and
salts, analogues, and derivatives thereof; lecithins, lysolecithin,
phospholipids, lysophospholipids and derivatives thereof; salts of
alkylsulfates; salts of fatty acids; sodium docusate; acyl
lactylates; mono- and di-acetylated tartaril acid esters of mono-
and di-glycerides; succinylated monoglycerides; citric acid esters
of mono- and di-glycerides; carnitines; and mixtures thereof.
[0102] More specifically, preferred ionic surfactants are lecithin,
lysolecithin, phosphatidylcholine, phosphatidylethanolamine,
phosphatidylglycerol, phosphatidic acid, phosphatidylserine,
lysophosphatidylcholine, lysophosphatidylethanolamine,
lysophosphatidylglycerol, lysophosphatidic acid,
lysophosphatidyiserine, PEG-phosphatidylethanolamine,
PVP-phosphatidylethanolamine, lactylic esters of fatty acids,
stearoyl-2-lactylate, stearoyl lactylate, succinylated
monoglycerides, mono- and di-acetylated tartaric acid esters of
mono- and di-glycerides, citric acid esters of mono- and
di-glycerides, cholate, taurocholate, glycocholate, deoxycholate,
taurodeoxycholate, chenodeoxycholate, glycodcoxycholate,
glycochenodeoxycholate, taurochenodeoxycholate, ursodeoxycholate,
tauroursodeoxycholate, glycoursodeoxycholate, cholylsarcosine,
N-methyl taurocholate, caproate, caprylate, caprate, laurate,
myristate, palmitate, oleate, ricinoleate, linoleate, linolenate,
stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl
carnitines, palmitoyl carnitines, myristoyl carnitines, and salts
and mixtures thereof.
[0103] Particularly preferred ionic surfactants are lecithin,
lysolecithin, phosphatidylcholine, phosphatidylethanolamine,
phosphatidylglycerol, lysophosphatidylcholine,
PEG-phosphatidylethanolamine, lactylic esters of fatty acids,
stearoyl-2-lactylate, stearoyl lactylate, succinylated
monoglycerides, mono- and di-acetylated tartaric acid esters of
mono- and di-glycerides, citric acid esters of mono- and
di-glycerides cholate, taurocholate glycocholate, deoxycholate,
taurodeoxycholate, glycodeoxycholate, cholylsarcosine, caproate,
caprylate, caprate, laurate, oleate, lauryl sulfate, docusate, and
salts and mixtures thereof, with the most preferred ionic
surfactants being lecithin, lactylic esters of fatty acids,
stearoyl-2-lactylate, stearoyl lactylate, succinylated
monoglycerides, mono- and di-acetylated tartaric acid esters of
mono- and di-glycerides, citric acid esters of mono- and
di-glycerides, taurocholate, caprylate, caprate, oleate, lauryl
sulfate, docusate, and salts and mixtures thereof.
[0104] Preferred lipophilic surfactants are alcohols;
polyoxyethylene alkylethers; fatty acids; glycerol fatty acid
esters; acetylated glycerol fatty acid esters; lower alcohol fatty
acid esters; polyethylene glycol fatty acid esters; polyethylene
glycol glycerol fatty acid esters; polypropylene glycol fatty acid
esters; polyoxyethylene glycerides; lactic acid derivatives of
mono- and di-glycerides; propylene glycol diglycerides; sorbitan
fatty acid esters; polyoxyethylene sorbitan fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; transesterified
vegetable oils; sterols; sterol derivatives; sugar esters; sugar
ethers; sucroglycerides; polyoxyethylene vegetable oils; and
polyoxyethylene hydrogenated vegetable oils.
[0105] As with the hydrophilic surfactants, lipophilic surfactants
can be reaction mixtures of polyols and fatty acids, glycerides,
vegetable oils, hydrogenated vegetable oils, and sterols.
[0106] Preferably, the lipophilic surfactant is selected from the
group consisting of fatty acids; lower alcohol fatty acid esters;
polyethylene glycol glycerol fatty acid esters; polypropylene
glycol fatty acid esters; polyoxyethylene glycerides; glycerol
fatty acid esters; acetylated glycerol fatty acid esters; lactic
acid derivatives of mono- and di-glycerides; sorbitan fatty acid
esters; polyoxyethylene sorbitan fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; polyoxyethylene
vegetable oils; polyoxyethylene hydrogenated vegetable oils; and
reaction mixtures of polyols and fatty acids, glycerides, vegetable
oils, hydrogenated vegetable oils, and sterols.
[0107] More preferred are lower alcohol fatty acids esters;
polypropylene glycol fatty acid esters; propylene glycol fatty acid
esters; glycerol fatty acid esters; acetylated glycerol fatty acid
esters; lactic acid derivatives of mono- and di-glycerides;
sorbitan fatty acid esters; polyoxyethylene vegetable oils; and
mixtures thereof with glycerol fatty acid esters and acetylated
glycerol fatty acid esters being most preferred. Among the glycerol
fatty acid esters, the esters are preferably mono- or diglycerides,
or mixtures of mono- and diglycerides, where the fatty acid moiety
is a C.sub.6 to C.sub.22 fatty acid.
[0108] Also preferred are lipophilic surfactants that are the
reaction mixture of polyols and fatty acids, glycerides, vegetable
oils, hydrogenated vegetable oils, and sterols. Preferred polyols
are polyethylene glycol, sorbitol, propylene glycol, and
pentaerythritol.
[0109] 3. Triglycerides
[0110] For compositions of the present invention that include a
lipophilic additive, the lipophilic component can be a lipophilic
surfactant or a triglyceride. Preferred triglycerides are those
which solidify at ambient room temperature, with or without
addition of appropriate additives, or those which in combination
with particular surfactants and/or active ingredients solidify at
room temperature. Examples of triglycerides suitable for use in the
present invention are shown in Table 19. In general, these
triglycerides are readily available from commercial sources. For
several triglycerides, representative commercial products and/or
commercial suppliers are listed.
TABLE-US-00019 TABLE 19 Triglycerides TRIGLYCERIDE COMMERCIAL
SOURCE Aceituno oil Almond oil Super Refined Almond Oil (Croda)
Arachis oil Babassu oil Blackcurrant seed oil Borage oil Buffalo
ground oil Candlenut oil Canola oil Lipex 108 (Abitec) Caster oil
Chinese vegetable tallow oil Cocoa butter Coconut oil Coffee seed
oil Pureco 76 (Abitec) Corn oil Super Refined Corn Oil (Croda)
Cottonseed oil Super Refined Cottonseed Oil (Croda) Crambe oil
Cuphea species oil Evening primrose oil Grapeseed oil Groundnut oil
Hemp seed oil Illipe butter Kapok seed oil Linseed oil Menhaden oil
Super Refined Menhaden Oil (Croda) Mowrah butter Mustard seed oil
Oiticica oil Olive oil Super Refined Olive Oil (Croda) Palm oil
Palm kernel oil Peanut oil Super Refined Peanut Oil (Croda) Poppy
seed oil Rapeseed oil Rice bran oil Safflower oil Super Refined
Safflower Oil (Croda) Sal fat Sesame oil Super Refined Sesame Oil
(Croda) Shark liver oil Super Refined Shark Liver Oil (Croda) Shea
nut oil Soybean oil Super Refined Soybean Oil (Croda) Stillingia
oil Sunflower oil Tall oil Tea sead oil Tobacco seed oil Tung oil
(China wood oil) Ucuhuba Vernonia oil Wheat germ oil Super Refined
Wheat Germ Oil (Croda) Hydrogenated caster oil Castorwax
Hydrogenated coconut oil Pureco 100 (Abitec) Hydrogenated
cottonseed oil Dritex C (Abitec) Hydrogenated palm oil Dritex PST
(Abitec); Softisan154 (Huls) Hydrogenated soybean oil Sterotex HM
NF (Abitec); Dritex S (Abitec) Hydrogenated vegetable oil Sterotex
NF (Abitec): Hydrokote M (Abitec) Hydrogenated cottonseed/castor
oil Sterotex K (Abitec) Partially hydrogenated soybean oil
Hydrokote AP5 (Abitec) Partially soy and cottonseed oil Apex B
(Abitec) Glyceryl tributyrate (Sigma) Glyceryl tricaproate (Sigma)
Glyceryl tricaprylate (Sigma) Glyceryl tricaprate Captex 1000
(Abitec) Glyceryl trundecanoate Captex 8227 (Abitec) Glyceryl
trilaurate (Sigma) Glyceryl trimyristate Dynasan 114 (Huls)
Glyceryl tripalmitate Dynasan 116 (Huls) Glyceryl tristearate
Dynasan 118 (Huls) Glyceryl triarcidate (Sigma) Glyceryl
trimyristoleate (Sigma) Glyceryl tripalmitoleate (Sigma) Glyceryl
trioleate (Sigma) Glyceryl trilinoleate (Sigma) Glyceryl
trilinolenate (Sigma) Glyceryl tricaprylate/caprate Captex 300
(Abitec); Captex 355 (Abitec); Miglyol 810 (Huls); Miglyol 812
(Huls) Glyceryl tricaprylate/caprate/laurate Captex 350 (Abitec)
Glyceryl tricaprylate/caprate/linoleate Captex 810 (Abitec);
Miglyol 818 (Huls) Glyceryl tricaprylate/caprate/stearate Softisan
378 (Huls); (Larodan) Glyceryl tricaprylate/laurate/stearate
(Larodan) Glyceryl 1,2-caprylate-3-linoleate (Larodan) Glyceryl
1,2-caprate-3-stearate (Larodan) Glyceryl 1,2-laurate-3-myristate
(Larodan) Glyceryl 1,2-myristate-3-laurate (Larodan) Glyceryl
1,3-palmitate-2-butyrate (Larodan) Glyceryl 1,3-stearate-2-caprate
(Larodan) Glyceryl 1,2-linoleate-3-caprylate (Larodan)
[0111] Fractionated triglycerides, modified triglycerides,
synthetic triglycerides, and mixtures of triglycerides are also
within the scope of the invention.
[0112] Preferred triglycerides include vegetable oils, fish oils,
animal fats, hydrogenated vegetable oils, partially hydrogenated
vegetable oils, medium and long-chain triglycerides, and structured
triglycerides. It should be appreciated that several commercial
surfactant compositions contain small to moderate amounts of
triglycerides, typically as a result of incomplete reaction of a
triglyceride starting material in, for example, a
transesterification reaction. Such commercial surfactant
compositions, while nominally referred to as "surfactants," may be
suitable to provide all or part of the triglyceride component for
the compositions of the present invention. Examples of commercial
surfactant compositions containing triglycerides include some
members of the surfactant families Gelucires (Gattefosse), Maisines
(Gattefosse), and Imwitors (Huls). Specific examples of these
compositions are: Gelucire 44/14 (saturated polyglycolized
glycerides); Gelucire 50/13 (saturated polyglycolized glycerides);
Gelucire 53/10 (saturated polyglycolized glycerides); Gelucire
33/01 (semi-synthetic triglycerides of C.sub.8-C.sub.18 saturated
fatty acids); Gelucire 39/01 (semi-synthetic glycerides); other
Gelucires, such as 37/06, 43/01, 35/10, 37/02, 46/07, 48/09, 50/02,
62/05, etc.; Maisine 35-I (linoleic glycerides); and Imwitor 742
(caprylic/capric glycerides).
[0113] Still other commercial surfactant compositions having
significant triglyceride content are known to those skilled in the
art. It should be appreciated that such compositions, which contain
triglycerides as well as surfactants, may be suitable to provide
all or part of the triglyceride component of the compositions of
the present invention, as well as all or part of the surfactant
component.
[0114] 4. Substrates
[0115] The substrate of the compositions of the present invention
can be a powder or a multiparticulate, such as a granule, a pellet,
a bead, a spherule, a beadlet, a microcapsule, a millisphere, a
nanocapsule, a nanosphere, a microsphere, a platelet, a minitablet,
a tablet or a capsule. A powder constitutes a finely divided
(milled, micronized, nanosized, precipitated) form of an active
ingredient or additive molecular aggregates or a compound aggregate
of multiple components or a physical mixture of aggregates of an
active ingredient and/or additives. Such substrates can be formed
of various materials known in the art, such as, for example:
sugars, such as lactose, sucrose or dextrose; polysaccharides, such
as maltodextrin or dextrates; starches; cellulosics, such as
microcrystalline cellulose or microcrystalline cellulose/sodium
carboxymethyl cellulose; inorganics, such as dicalcium phosphate,
hydroxyapatite, tricalcium phosphate, talc, or titania; and
polyols, such as mannitol, xylitol, sorbitol or cyclodextrin.
[0116] The substrate can also be formed of any of the active
ingredients, surfactants, triglycerides, solubilizers or additives
described herein. In one particular embodiment, the substrate is a
solid form of an additive, an active ingredient, a surfactant, or a
triglyceride; a complex of an additive, surfactant or triglyceride
and an active ingredient; a coprecipitate of an additive,
surfactant or triglyceride and an active ingredient, or a mixture
thereof.
[0117] It should be emphasized that the substrate need not be a
solid material, although often it will be a solid. For example, the
encapsulation coat on the substrate may act as a solid "shell"
surrounding and encapsulating a liquid or semi-liquid substrate
material. Such substrates are also within the scope of the present
invention, as it is ultimately the carrier, of which the substrate
is a part, which must be a solid.
[0118] 5. Additives
[0119] The solid pharmaceutical compositions of the present
invention can optionally include one or more additives, sometimes
referred to as excipients. The additives can be contained in an
encapsulation coat in compositions, which include an encapsulation
coat, or can be part of the solid carrier, such as coated to an
encapsulation coat, or contained within the components forming the
solid carrier. Alternatively, the additives can be contained in the
pharmaceutical composition but not part of the solid carrier
itself. Specific, non-limiting examples of additives are described
below.
[0120] Suitable additives are those commonly utilized to facilitate
the processes involving the preparation of the solid carrier, the
encapsulation coating, or the pharmaceutical dosage form. These
processes include agglomeration, air suspension chilling, air
suspension drying, balling, coacervation, comminution, compression,
pelletization, cryopelletization, extrusion, granulation,
homogenization, inclusion complexation, lyophilization,
nanoencapsulation, melting, mixing, molding, pan coating, solvent
dehydration, sonication, spheronization, spray chilling, spray
congealing, spray drying, or other processes known in the art. The
additive can also be pre-coated or encapsulated. Appropriate
coatings are well known in the art, and are further described in
the sections below. Based on the functionality of the additives,
examples of the additives are as follows:
[0121] 5.1 Solubilizers
[0122] The pharmaceutical compositions of the present invention can
optionally include one or more solubilizers, i.e., additives to
increase the solubility of the pharmaceutical active ingredient or
other composition components in the solid carrier. Suitable
solubilizers for use in the compositions of the present invention
include:
[0123] alcohols and polyols, such as ethanol, isopropanol, butanol,
benzyl alcohol, ethylene glycol, propylene glycol, butanediols and
isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol,
transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene
glycol, polyvinylalcohol, hydroxypropylmethyl cellulose and other
cellulose derivatives, cyclodextrins and cyclodextrin
derivatives;
[0124] ethers of polyethylene glycols having an average molecular
weight of about 200 to about 6000, such as tetrahydrofurfuryl
alcohol PEG ether (glycofurol, available commercially from BASF
under the trade name Tetraglycol) or methoxy PEG (Union
Carbide);
[0125] amides, such as 2-pyrrolidone, 2-piperidone,
.epsilon.-caprolactam, N-alkylpyrrolidone,
N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam,
dimethylacetamide, and polyvinylpyrrolidone;
[0126] esters, such as ethyl propionate, tributylcitrate, acetyl
triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl
oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene
glycol monoacetate, propylene glycol diacetate,
.epsilon.-caprolactone and isomers thereof, .delta.-valerolactone
and isomers thereof, .beta.-butyrolactone and isomers thereof;
and
[0127] and other solubilizes known in the art, such as dimethyl
acetamide, dimethyl isosorbide (Arlasolve DMI (ICI)), N-methyl
pyrrolidones (Pharmasolve (ISP)), monooctanoin, diethylene glycol
monoethyl ether (available from Gattefosse under the trade name
Transcutol), and water.
[0128] Mixtures of solubilizers are also within the scope of the
invention. Except as indicated, these compounds are readily
available from standard commercial sources.
[0129] Preferred solubilizers include triacetin, triethylcitrate,
ethyl oleate, ethyl caprylate, dimethylacetamide,
N-methylpyrrolidone, N-hydroxyethylpyrrolidine,
polyvinylpyrrolidone, hydroxypropylmethyl cellulose, hydroxypropyl
cyclodextrins, ethanol, polyethylene glycol 200-600, glycofurol,
transcutol, propylene glycol, and dimethyl isosorbide. Particularly
preferred solubilizers include sorbitol, glycerol, triacetin, ethyl
alcohol, PEG-400, glycofurol and propylene glycol.
[0130] The amount of solubilizer that can be included in
compositions of the present invention is not particularly limited.
Of course, when such compositions are ultimately administered to a
patient, the amount of a given solubilizer is limited to a
bioacceptable amount, which is readily determined by one of skill
in the art. In some circumstances, it may be advantageous to
include amounts of solubilizers far in excess of bioacceptable
amounts, for example, to maximize the concentration of active
ingredient, with excess solubilizer removed prior to providing the
composition to a patient using conventional techniques, such as
distillation or evaporation.
[0131] 5.2. Enzyme Inhibitors
[0132] When the active ingredient is subject to enzymatic
degradation, the compositions can include an enzyme inhibiting
agent. Enzyme inhibiting agents are shown for example, in
Bernskop-Schnurch, A., "The use of inhibitory agents to overcome
enzymatic barrier to perorally administered therapeutic peptides
and proteins," J. Controlled Release 52, 1-16 (1998), the
disclosure of which is incorporated herein by reference.
[0133] Generally, inhibitory agents can be divided into the
following classes:
[0134] Inhibitors that are not based on amino acids, such as
P-aminobenzamidine, FK-448, camostat mesylate, sodium
glycocholate;
[0135] Amino acids and modified amino acids, such as aminoboronic
acid derivatives and n-acetylcysteine;
[0136] Peptides and modified peptides, such as bacitracin,
phosphinic acid dipeptide derivatives, pepstatin, antipain,
leupeptin, chymostatin, elastatin, bestatin, phosphoramindon,
puromycin, cytochalasin potatocarboxy peptidase inhibitor, and
amastatin;
[0137] Polypeptide protease inhibitors, such as aprotinin (bovine
pancreatic trypsin inhibitor), Bowman-Birk inhibitor and soybean
trypsin inhibitor, chicken egg white trypsin inhibitor, chicken
ovoinhibitor, and human pancreatic trypsin inhibitor. Complexing
agents, such as EDTA, EGTA, 1,10-phenanthroline and
hydroxychinoline; and
[0138] Mucoadhesive polymers and polymer-inhibitor conjugates, such
as polyacrylate derivatives, chitosan, cellulosics, chitosan-EDTA,
chitosan-EDTA-antipain, polyacrylic acid-bacitracin, carboxymethyl
cellulose-pepstatin, polyacrylic acid-Bwoman-Birk inhibitor.
[0139] The choice and levels of the enzyme inhibitor are based on
toxicity, specificity of the proteases and the potency of the
inhibition. The inhibitor can be suspended or solubilized in the
composition preconcentrate, or added to the aqueous diluent or as a
beverage.
[0140] Without wishing to be bound by theory, it is believed that
an inhibitor can function solely or in combination as: a
competitive inhibitor, by binding at the substrate binding site of
the enzyme, thereby preventing the access to the substrate;
examples of inhibitors believed to operate by this mechanism are
antipain, elastatinal and the Bowman Birk inhibitor, a
non-competitive inhibitor which can be simultaneously bound to the
enzyme site along with the substrate, as their binding sites are
not identical; and/or a complexing agent due to loss in enzymatic
activity caused by deprivation of essential metal ions out of the
enzyme structure.
[0141] 5.3 Other Additives
[0142] Other additives conventionally used in pharmaceutical
compositions can be included, and these additives are well known in
the art. Such additives include:
[0143] anti-adherents (anti-sticking agents, glidants, flow
promoters, lubricants) such as talc, magnesium stearate, fumed
silica (Carbosil, Aerosil), micronized silica (Syloid No. FP 244,
Grace U.S.A.), polyethylene glycols, surfactants, waxes, stearic
acid, stearic acid salts, stearic acid derivatives, starch,
hydrogenated vegetable oils, sodium benzoate, sodium acetate,
leucine, PEG-4000 and magnesium lauryl sulfate;
[0144] anticoagulants, such as acetylated monoglycerides;
[0145] antifoaming agents, such as long-chain alcohols and silicone
derivatives;
[0146] antioxidants, such as BHT, BHA, gallic acid, propyl gallate,
ascorbic acid, ascorbyl palmitate,
4-hydroxymethyl-2,6-di-tert-butyl phenol, and tocopheryl;
[0147] binders (adhesives), i.e., agents that impart cohesive
properties to powdered materials through particle-particle bonding,
such as matrix binders (dry starch, dry sugars), film binders (PVP,
starch paste, celluloses, bentonite, sucrose), and chemical binders
(polymeric cellulose derivatives, such as carboxy methyl cellulose,
HPC and HPMC; sugar syrups; corn syrup; water soluble
polysaccharides such as acacia, tragacanth, guar and alginates;
gelatin; gelatin hydrolysate; agar, sucrose; dextrose; and
non-cellulosic binders, such as PVP, PEG, vinyl pyrrolidone
copolymers, pregelatinized starch, sorbitol, and glucose);
[0148] bufferants, where the acid is a pharmaceutically acceptable
acid, such as hydrochloric acid, hydrobromic acid, hydriodic acid,
sulfuric acid, nitric acid, boric acid, phosphoric acid, acetic
acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid,
amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid,
carbonic acid, citric acid, fatty acids, formic acid, fumaric acid,
gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic
acid, maleic acid, methanesulfonic acid, oxalic acid,
para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic
acid, salicylic acid, stearic acid, succinic acid, tannic acid,
tartaric acid, thioglycolic acid, toluenesulfonic acid and uric
acid, and where the base is a pharmaceutically acceptable base,
such as an amino acid, an amino acid ester, ammonium hydroxide,
potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate,
aluminum hydroxide, calcium carbonate, magnesium hydroxide,
magnesium aluminum silicate, synthetic aluminum silicate, synthetic
hydrotalcite, magnesium aluminum hydroxide, diisopropylethylamine,
ethanolamine, ethylenediamine, triethanolamine, triethylamine,
triisopropanolamine, or a salt of a pharmaceutically acceptable
cation and acetic acid, acrylic acid, adipic acid, alginic acid,
alkanesulfonic acid, an amino acid, ascorbic acid, benzoic acid,
boric acid, butyric acid, carbonic acid, citric acid, a fatty acid,
formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid,
isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid,
oxalic acid, para-bromophenylsulfonic acid, propionic acid,
p-toluenesulfonic acid, salicylic acid, stearic acid, succinic
acid, tannic acid, tartaric acid, thioglycolic acid,
toluenesulfonic acid, and uric acid;
[0149] chelating agents, such as EDTA and EDTA salts;
[0150] coagulants, such as alginates;
[0151] colorants or opaquants, such as titanium dioxide, food dyes,
lakes, natural vegetable colorants, iron oxides, silicates,
sulfates, magnesium hydroxide and aluminum hydroxide;
[0152] coolants, such as halogenated hydrocarbons (e.g.,
trichloroethane, trichloroethylene, dichloromethane,
fluorotrichloromethane), diethylether and liquid nitrogen;
[0153] cryoprotectants, such as trehelose, phosphates, citric acid,
tartaric acid, gelatin, dextran and mannitol;
[0154] diluents or fillers, such as lactose, mannitol, talc,
magnesium stearate, sodium chloride, potassium chloride, citric
acid, spray-dried lactose, hydrolyzed starches, directly
compressible starch, microcrystalline cellulose, cellulosics,
sorbitol, sucrose, sucrose-based materials, calcium sulfate,
dibasic calcium phosphate and dextrose;
[0155] disintegrants or super disintegrants, such as croscarmellose
sodium, starch, starch derivatives, clays, gums, cellulose,
cellulose derivates, alginates, crosslinked polyvinylpyrrolidone,
sodium starch glycolate and microcrystalline cellulose;
[0156] hydrogen bonding agents such as magnesium oxide;
[0157] flavorants or desensitizers, such as spray-dried flavors,
essential oils and ethyl vanillin;
[0158] ion-exchange resins, such as styrene/divinyl benzene
copolymers, and quaternary ammonium compounds;
[0159] plasticizers such as polyethylene glycol, citrate esters
(e.g., triethyl citrate, acetyl triethyl citrate, acetyltributyl
citrate), acetylated monoglycerides, glycerin, triacetin, propylene
glycol, phthalate esters (e.g., diethyl phthalate, dibutyl
phthalate), castor oil, sorbitol and dibutyl seccate;
[0160] preservatives, such as ascorbic acid, boric acid, sorbic
acid, benzoic acid, and salts thereof, parabens, phenols, benzyl
alcohol, and quaternary ammonium compounds;
[0161] solvents, such as alcohols, ketones, esters, chlorinated
hydrocarbons and water;
[0162] sweeteners, including natural sweeteners such as maltose,
sucrose, glucose, sorbitol, glycerin and dextrins, and artificial
sweeteners, such as aspartame, saccharine and saccharine salts;
and
[0163] thickeners (viscosity modifiers, thickening agents), such as
sugars, polyvinylpyrrolidone, cellulosics, polymers and
alginates.
[0164] Additives can also be materials such as proteins (e.g.,
collagen, gelatin, Zein, gluten, mussel protein, lipoprotein);
carbohydrates (e.g., alginates, carrageenan, cellulose derivatives,
pectin, starch, chitosan); gums (e.g., xanthan gum, gum arabic);
spermaceti; natural or synthetic waxes; carnuaba wax; fatty acids
(e.g., stearic acid, hydroxystearic acid); fatty alcohols; sugars;
shellacs, such as those based on sugars (e.g., lactose, sucrose,
dextrose) or starches; polysaccharide-based shellacs (e.g.,
maltodextrin and maltodextrin derivatives, dextrates, cyclodextrin
and cyclodextrin derivatives); cellulosic-based shellacs (e.g.,
microcrystalline cellulose, sodium carboxymethyl cellulose,
hydroxypropylmethyl cellulose, ethyl cellulose, hydroxypropyl
cellulose, cellulose acetate, cellulose nitrate, cellulose acetate
butyrate, cellulose acetate trimellitate, carboxymethylethyl
cellulose, hydroxypropylmethyl cellulose phthalate); inorganics,
such as dicalcium phosphate, hydroxyapatite, tricalcium phosphate,
talc and titania; polyols, such as mannitol, xylitol and sorbitol;
polyethylene glycol esters; and polymers, such as alginates,
poly(lactide coglycolide), gelatin, crosslinked gelatin, and
agar-agar.
[0165] It should be appreciated that there is considerable overlap
between the above-listed additives in common usage, since a given
additive is often classified differently by different practitioners
in the field, or is commonly used for any of several different
functions. Thus, the above-listed additives should be taken as
merely exemplary, and not limiting, of the types of additives that
can be included in compositions of the present invention. The
amounts of such additives can be readily determined by one skilled
in the art, according to the particular properties desired.
[0166] 6. Dosage Forms
[0167] The compositions of the present invention can be processed
by agglomeration, air suspension chilling, air suspension drying,
balling, coacervation, coating, comminution, compression,
cryopelletization, encapsulation, extrusion, wet granulation, dry
granulation, homogenization, inclusion complexation,
lyophilization, melting, microencapsulation, mixing, molding, pan
coating, solvent dehydration, sonication, spheronization, spray
chilling, spray congealing, spray drying, or other processes known
in the art. The compositions can be provided in the form of a
minicapsule, a capsule, a tablet, an implant, a troche, a lozenge
(minitablet), a temporary or permanent suspension, an ovule, a
suppository, a wafer, a chewable tablet, a quick or fast dissolving
tablet, an effervescent tablet, a buccal or sublingual solid, a
granule, a film, a sprinkle, a pellet, a bead, a pill, a powder, a
triturate, a platelet, a strip or a sachet. Compositions can also
be administered as a "dry syrup," where the finished dosage form is
placed directly on the tongue and swallowed or followed with a
drink or beverage. These forms are well known in the art and are
packaged appropriately. The compositions can be formulated for
oral, nasal, buccal, ocular, urethral, transmucosal, vaginal,
topical or rectal delivery, although oral delivery is presently
preferred.
[0168] The pharmaceutical composition and/or the solid carrier
particles can be coated with one or more enteric coatings, seal
coatings, film coatings, barrier coatings, compress coatings, fast
disintegrating coatings, or enzyme degradable coatings. Multiple
coatings can be applied for desired performance. Further, the
dosage form can be designed for immediate release, pulsatile
release, controlled release, extended release, delayed release,
targeted release, synchronized release, or targeted delayed
release. For release/absorption control, solid carriers can be made
of various component types and levels or thicknesses of coats, with
or without an active ingredient. Such diverse solid carriers can be
blended in a dosage form to achieve a desired performance. The
definitions of these terms are known to those skilled in the art.
In addition, the dosage form release profile can be effected by a
polymeric matrix composition, a coated matrix composition, a
multiparticulate composition, a coated multiparticulate
composition, an ion-exchange resin-based composition, an
osmosis-based composition, or a biodegradable polymeric
composition. Without wishing to be bound by theory, it is believed
that the release may be effected through favorable diffusion,
dissolution, erosion, ion-exchange, osmosis or combinations
thereof.
[0169] When formulated as a capsule, the capsule can be a hard or
soft gelatin capsule, a starch capsule, or a cellulosic capsule.
Although not limited to capsules, such dosage forms can further be
coated with, for example, a seal coating, an enteric coating, an
extended release coating, or a targeted delayed release coating.
These various coatings are known in the art, but for clarity, the
following brief descriptions are provided:
[0170] Seal coating, or coating with isolation layers: Thin layers
of up to 20 microns in thickness can be applied for variety of
reasons, including for particle porosity reduction, to reduce dust,
for chemical protection, to mask taste, to reduce odor, to minimize
gastrointestinal irritation, etc. The isolating effect is
proportional to the thickness of the coating. Water soluble
cellulose ethers are preferred for this application. HPMC and ethyl
cellulose in combination, or Eudragit E100, may be particularly
suitable for taste masking applications. Traditional enteric
coating materials listed elsewhere can also be applied to form an
isolating layer.
[0171] Extended release coating: The term "extended release
coating" as used herein means a coating designed to effect delivery
over an extended period of time. Preferably, the extended release
coating is a pH-independent coating formed of, for example, ethyl
cellulose, hydroxypropyl cellulose, methylcellulose, hydroxymethyl
cellulose, hydroxyethyl cellulose, acrylic esters, or sodium
carboxymethyl cellulose. Various extended release dosage forms can
be readily designed by one skilled in art to achieve delivery to
both the small and large intestines, to only the small intestine,
or to only the large intestine, depending upon the choice of
coating materials and/or coating thickness.
[0172] Enteric coating: The term "enteric coating" as used herein
relates to a mixture of pharmaceutically acceptable excipients
which is applied to, combined with, mixed with or otherwise added
to the carrier or composition. The coating may be applied to a
compressed or molded or extruded tablet, a gelatin capsule, and/or
pellets, beads, granules or particles of the carrier or
composition. The coating may be applied through an aqueous
dispersion or after dissolving in appropriate solvent. Additional
additives and their levels, and selection of a primary coating
material or materials will depend on the following properties:
[0173] 1. resistance to dissolution and disintegration in the
stomach;
[0174] 2. impermeability to gastric fluids and drug/carrier/enzyme
while in the stomach;
[0175] 3. ability to dissolve or disintegrate rapidly at the target
intestine site;
[0176] 4. physical and chemical stability during storage;
[0177] 5. non-toxicity;
[0178] 6. easy application as a coating (substrate friendly);
and
[0179] 7. economical practicality.
[0180] Dosage forms of the compositions of the present invention
can also be formulated as enteric coated delayed release oral
dosage forms, i.e., as an oral dosage form of a pharmaceutical
composition as described herein which utilizes an enteric coating
to effect release in the lower gastrointestinal tract. The enteric
coated dosage form may be a compressed or molded or extruded
tablet/mold (coated or uncoated) containing granules, pellets,
beads or particles of the active ingredient and/or other
composition components, which are themselves coated or uncoated.
The enteric coated oral dosage form may also be a capsule (coated
or uncoated) containing pellets, beads or granules of the solid
carrier or the composition, which are themselves coated or
uncoated.
[0181] The term "delayed release" as used herein refers to the
delivery so that the release can be accomplished at some generally
predictable location in the lower intestinal tract more distal to
that which would have been accomplished if there had been no
delayed release alterations. The preferred method for delay of
release is coating. Any coatings should be applied to a sufficient
thickness such that the entire coating does not dissolve in the
gastrointestinal fluids at pH below about 5, but does dissolve at
pH about 5 and above. It is expected that any anionic polymer
exhibiting a pH-dependent solubility profile can be used as an
enteric coating in the practice of the present invention to achieve
delivery to the lower gastrointestinal tract. The preferred
polymers for use in the present invention are anionic carboxylic
polymers. The more preferred polymers and compatible mixtures
thereof, and some of their properties, include, but are not limited
to:
[0182] Shellac, also called purified lac, a refined product
obtained from the resinous secretion of an insect. This coating
dissolves in media of pH>7.
[0183] Acrylic polymers (preferred). The performance of acrylic
polymers (primarily their solubility in biological fluids) can vary
based on the degree and type of substitution. Examples of suitable
acrylic polymers include methacrylic acid copolymers and ammonio
methacrylate copolymers. The Eudragit series E, L, S, RI, RS and NE
(Rohm Pharma) are available as solubilized in organic solvent,
aqueous dispersion, or dry powders. The Eudragit series RL, NE, and
RS are insoluble in the gastrointestinal tract but are permeable
and are used primarily for extended release. The Eudragit series E
dissolve in the stomach. The Eudragit series L, L-30D and S are
insoluble in stomach and dissolve in the intestine.
[0184] Cellulose Derivatives (also preferred). Examples of suitable
cellulose derivatives are: ethyl cellulose; reaction mixtures of
partial acetate esters of cellulose with phthalic anhydride. The
performance can vary based on the degree and type of substitution.
Cellulose acetate phthalate (CAP) dissolves in pH>6. Aquateric
(FMC) is an aqueous based system and is a spray dried CAP
psuedolatex with particles <1 .mu.m. Other components in
Aquateric can include pluronics, Tweens, and acetylated
monoglycerides; cellulose acetate trimellitate (Eastman);
methylcellulose (Pharmacoat, Methocel); hydroxypropylmethyl
cellulose phthalate (HPMCP). The performance can vary based on the
degree and type of substitution. HP-50, HP-55, HP-55S, HP-55F
grades are suitable; hydroxypropylmethyl cellulose succinate
(HPMCS; AQOAT (Shin Etsu)). The performance can vary based on the
degree and type of substitution. Suitable grades include AS-LG
(LF), which dissolves at pH 5, AS-MG (MF), which dissolves at pH
5.5, and AS-HG (HF), which dissolves at higher pH. These polymers
are offered as granules, or as fine powders for aqueous
dispersions;
[0185] Poly Vinyl Acetate Phthalate (PVAP). PVAP dissolves in
pH>5, and it is much less permeable to water vapor and gastric
fluids; and
[0186] Cotteric (by Colorcon).
[0187] Combinations of the above materials can also be used.
[0188] The coating can, and usually does, contain a plasticizer and
possibly other coating excipients such as colorants, talc, and/or
magnesium stearate, which are well known in the art. Suitable
plasticizers include: triethyl citrate (Citroflex 2), triacetin
(glyceryl triacetate), acetyl triethyl citrate (Citroflec A2),
Carbowax 400 (polyethylene glycol 400), diethyl phthalate, tributyl
citrate, acetylated monoglycerides, glycerol, fatty acid esters,
propylene glycol, and dibutyl phthalate. In particular, anionic
carboxylic acrylic polymers usually will contain 10-25% by weight
of a plasticizer, especially dibutyl phthalate, polyethylene
glycol, triethyl citrate and triacetin. Conventional coating
techniques such as spray or pan coating are employed to apply
coatings. The coating thickness must be sufficient to ensure that
the oral dosage form remains intact until the desired site of
topical delivery in the lower intestinal tract is reached.
[0189] Colorants, detackifiers, surfactants, antifoaming agents,
lubricants, stabilizers such as hydroxypropylcellulose, acid/base
may be added to the coatings besides plasticizers to solubilize or
disperse the coating material, and to improve coating performance
and the coated product.
[0190] A particularly suitable methacrylic copolymer is Eudragit
L.RTM., particularly L-30D.RTM. and Eudragit 100-55.RTM.,
manufactured by Rohm Pharma, Germany. In Eudragit L-30 D.RTM., the
ratio of free carboxyl groups to ester groups is approximately 1:1.
Further, the copolymer is known to be insoluble in gastrointestinal
fluids having pH below 5.5, generally 1.5-5.5, i.e., the pH
generally present in the fluid of the upper gastrointestinal tract,
but readily soluble or partially soluble at pH above 5.5, i.e., the
pH generally present in the fluid of lower gastrointestinal
tract.
[0191] Another methacrylic acid polymer which is suitable for use
in coating the composition or solid carrier which can be employed
in the compositions and methods described herein, either alone or
in combination with other coatings, is Eudragit S.RTM.,
manufactured by Rohm Pharma, Germany. Eudragit S differs from
Eudragit L-30-D only insofar as the ratio of free carboxyl groups
to ester groups is approximately 1:2. Eudragit S is insoluble at pH
below 5.5, but unlike Eudragit L-30-D, is poorly soluble in
gastrointestinal fluids having pH of 5.5-7.0, such as is present in
the small intestine media. This copolymer is soluble at pH 7.0 and
above, i.e., the pH generally found in the colon. Eudragit S can be
used alone as a coating to provide delivery of beginning at the
large intestine via a delayed release mechanism. In addition,
Eudragit S, being poorly soluble in intestinal fluids below pH 7,
can be used in combination with Eudragit L-30-D, soluble in
intestinal fluids above pH 5.5, in order to effect a delayed
release composition. The more Eudragit L-30 D used the more
proximal release and delivery begins, and the more Eudragit S used,
the more distal release and delivery begins. Both Eudragit L-30-D
and Eudragit S can be substituted with other pharmaceutically
acceptable polymers with similar pH solubility characteristics.
[0192] Preferred materials include shellac, acrylic polymers,
cellulosic derivatives, polyvinyl acetate phthalate, and mixtures
thereof. More preferred materials include Eudragit series E, L, S,
RL, RS, NE, L.RTM., L300.RTM., S.RTM., 100-55.RTM., cellulose
acetate phthalate, Aquateric, cellulose acetate trimellitate, ethyl
cellulose, hydroxypropyl methyl cellulose phthalate, hydroxypropyl
methyl cellulose succinate, poly vinyl acetate phthalate, and
Cotteric. Most preferred materials include Eudragit series L, L300,
S, L100-55, cellulose acetate phthalate, Aquateric, ethyl
cellulose, hydroxypropyl methyl cellulose phthalate, hydroxypropyl
methyl cellulose succinate, poly vinyl acetate phthalate, and
Cotteric.
[0193] Extended release and targeted delayed release coatings for
dosage forms of the compositions of the present invention are
described more completely in U.S. Pat. Nos. 5,622,721 and
5,686,105, the disclosures of which are incorporated herein by
reference in their entirety.
[0194] Fast-Disintegrating Coatings for Immediate Release:
Immediate release coating of solid carriers is commonly used to
improve product elegance as well as for a moisture barrier, and
taste and odor masking. Rapid breakdown of the film in gastric
media is important, leading to effective disintegration and
dissolution. Eudragit RD100 (Rohm) is an example of such a coating.
It is a combination of a water insoluble cationic methacrylate
copolymer with a water soluble cellulose ether. In powder form, it
is readily dispensable into an easily sprayable suspension that
dries to leave a smooth film. Such films rapidly disintegrate in
aqueous media at a rate that is independent of pH and film
thickness.
[0195] 7. Processes
[0196] The compositions of the present invention can be prepared by
a variety of processes to apply an encapsulation coat onto a
substrate or to form a substrate-free solid carrier such as a
multiparticulate or a powder. The commonly utilized coating and
pelletization processes include balling, spheronization, extrusion,
spray congealing, spray drying, pan coating, fluidized bed coating,
melt extrusion, crystallization, cryopelletization,
nanoencapsulation, coacervation, etc. It is also clear to one
skilled in the art that appropriate additives can also be
introduced to the composition or during the processes to facilitate
the preparation of the solid carrier or the dosage forms, depending
on the need of the individual process.
[0197] A coating process frequently involves spraying a coating
solution onto a substrate. The coating solution can be a molten
solution of the encapsulation coat composition free of a dispersing
medium. The coating solution can also be prepared by solubilizing
or suspending the composition of the encapsulation coat in an
aqueous medium, an organic solvent, a supercritical fluid, or a
mixture thereof. At the end of the coating process, the residual
dispersing medium can be further removed to a desirable level
utilizing appropriate drying processes, such as vacuum evaporation,
heating, freeze drying, etc.
[0198] A pelletization process typically involves preparing a
molten solution of the composition of the solid carrier or a
dispersion of the composition of the solid carrier solubilized or
suspended in an aqueous medium, an organic solvent, a supercritical
fluid, or a mixture thereof. Such solution or dispersion is then
passed through a certain opening to achieve the desired shape,
size, and other properties. Similarly, appropriate drying processes
can be adopted to control the level of the residual dispersing
medium, if necessary.
[0199] The processes described above, the combination of the
processes, or the modification of the processes are well know in
the art. Some of the processes are briefly described herein for
reference.
[0200] Balling, Spheronization or Extrusion
[0201] In a broad sense, pellets are very much like granules and
bead; the techniques for producing pellets can also produce
granules, beads, etc. Pellets, granules or beads are formed with
the aid of a pelletizer, spheronizer or extruder. The pelletizer,
spheronizer or extruder is able to form approximately spherical
bodies from a mass of finely divided particles continuously, by a
rolling or tumbling action on a flat or curved surface with the
addition of a liquid.
[0202] Pelletizers can be classified based on the angle of their
axis as horizontal drum or inclined dish pelletizers. Rotary
fluidized granulators can also be used for pelletization. A
standard fluidized drier bowl can be replaced with a rotating plate
as an air distributor. For granulation, a binder liquid is sprayed
from via one or two binary nozzles located axially to the
rotational movement of the powder bed. This operation results in
rounding of the granules to approximately spherical pellets. Such
balling or agitation techniques can be influenced by operating
conditions, such as bridging/binding liquid requirements, residence
time of the material in the pelletizer, speed and angle of
inclination of the pelletizer, amount of material fed to the
pelletizer, choice and levels of binder, etc. One skilled in the
art can readily adjust such factors to produce a satisfactory
product.
[0203] The components of the invention can also be self binding.
Liquid components can be pelletized with the aid of a suitable
solidifying, binding or thickening agents.
[0204] Similarly, the choice of an appropriate binder for a given
application is readily determined by one skilled in the art. At a
minimum, the binder must be capable of wetting the surfaces of the
particle being pelletized or granulated. Binders must have
sufficient wet strength to allow agglomerates to be handled, and
sufficient dry strength to make them suitable for their intended
purposes. Each process, however, makes use of a different system of
forces and may require a different agglomerate strength. The final
selection of the binder should be made on the basis of the type of
equipment that is used. The size and size distribution of pellets,
bulk density, strength and flow properties also affect the
performance of the pellets, and these properties can be adjusted by
one skilled in the art by the inclusion of additives, choice of
equipment, and processing conditions.
[0205] Extrusion
[0206] Extrusion is a well-known method of applying pressure to a
damp or melted composition until it flows through an orifice or a
defined opening. The extrudable length varies with the physical
characteristics of the material to be extruded, the method of
extrusion, and the process of manipulation of the particles after
extrusion. Various types of extrusion devices can be employed, such
as screw, sieve and basket, roll, and ram extruders.
[0207] Encapsulation by Extrusion: In this method, the lipid
composition in the form of an emulsion is added to a low moisture
melt of low maltodextrin, or sugar, or modified edible starch,
mixed and extruded into a cold bath. The solidified composition can
be further ground down. Optionally, centrifugal extrusion can be
utilized for efficiency.
[0208] Melt Extrusion: Components of the invention can be melted
and extruded with a continuous, solvent free extrusion process,
with or without inclusion of additives. Such a process is
well-established and well-known to skilled practitioners in the
art.
[0209] Spheronization
[0210] Spheronization is the process of converting material into
spheres, the shape with the lowest surface area to volume ratio.
Spheronization typically begins with damp extruded particles. The
extruded particles are broken into uniform lengths instantaneously
and gradually transformed into spherical shapes. In addition,
powdered raw materials, which require addition of either liquid or
material from a mixer, can be processed in an air-assisted
spheronizer.
[0211] Spray Congealing
[0212] Spray congealing is method that is generally used in
changing the structure of the materials, to obtain free flowing
powders from liquids and to provide pellets ranging in size from
about 0.25 to 2.0 mm. Spray congealing is process in which a
substance of interest is allowed to melt, disperse, or dissolve in
a hot melt of other additives, and is then sprayed into an air
chamber wherein the temperature is below the melting point of the
formulation components, to provide spherical congealed pellets. The
air removes the latent heat of fusion. The temperature of the
cooled air used depends on the freezing point of the product. The
particles are held together by solid bonds formed from the
congealed melts. Due to the absence of solvent evaporation in most
spray congealing processes, the particles are generally non porous
and strong, and remain intact upon agitation. The characteristics
of the final congealed product depend in part on the properties of
the additives used. The rate of feeding and inlet/outlet
temperatures are adjusted to ensure congealing of the atomized
liquid droplet. The feed should have adequate viscosity to ensure
homogeneity. The conversion of molten feed into powder is a single,
continuous step. Proper atomization and a controlled cooling rate
are critical to obtain high surface area, uniform and homogeneous
congealed pellets. Adjustment of these parameters is readily
achieved by one skilled in the art.
[0213] The spray congealing method is particularly suitable for
heat labile substances, since ambient temperature is used to dry,
and for moisture sensitive substances, since non-aqueous
compositions can be utilized. Spray congealing is similar to spray
drying, except that no solvent is utilized. Spray congealing is a
uniform and rapid process, and is completed before the product
comes in contact with any equipment surface. Most additives that
are solid at room temperature and melt without decomposition are
suitable for this method.
[0214] Conventional spray dryers operating with cool inlet air have
been used for spray congealing. Several methods of atomization of
molten mass can be employed, such as pressure, or pneumatic or
centrifugal atomization. For persons skilled in the spray
congealing art, it is well known that several formulation aspects,
such as matrix materials, viscosity, and processing factors, such
as temperature, atomization and cooling rate affect the quality
(morphology, particle size distribution, polymorphism and
dissolution characteristics) of spray congealed pellets. The spray
congealed particles may be used in tablet granulation form,
encapsulation form, or can be incorporated into a liquid suspension
form.
[0215] Solvent Dehydration (Spray Drying)
[0216] For compositions that are oily in nature, the spray drying
technique is commonly employed. The oily material is commonly mixed
with a polymeric material, such as gelatin, vegetable gum, modified
starch, dextrin, or other appropriate additives. An emulsifier is
added, if needed, to form an oil-in-water emulsion. The emulsion is
atomized into a column of heated air in a drying chamber, resulting
in rapid evaporation of water. Alternatively, the emulsion is
atomized directly into a polar solvent, such as isopropanol,
ethanol, glycerol or polyglycols, to dehydrate the aerosolized
particle. This method is particularly suitable for compositions
containing lipophilic actives or additives that result in
lipophilic cores. Spray drying/solvent dehydration can also be
applied to hydrophilic active ingredients or additives to form an
oil in water emulsion which is spray dried. This results in a
homogenous solid composition. Furthermore, water or organic solvent
based formulations can be spray dried by using inert process gas,
such as nitrogen, argon and the like.
[0217] Crystallization
[0218] Components of the present invention can be dissolved in
appropriate solvents and subjected to spherical crystallization
techniques well-known in the art.
[0219] Nanoencapsulation
[0220] Nanoencapsulation involves solubilizing an aqueous solution
of an active ingredient and other components in a weakly polar
vehicle. Micelles are formed with the active in an organic outer
phase. Then, an amphiphilic monomer is added to the lipophilic
external phase. The mixed micelles thus formed are then polymerized
with the aid of a suitable procedure, such as UV or gamma
radiation, heat, or chemical agents. The hardened solidified
micelles are made to undergo phase exchange by replacing an outer
lipophilic vehicle by water. By selecting appropriate monomers,
networking agents and auxiliary materials, nanoncapsules as small
as 80 to 250 nm can be prepared.
[0221] Supercritical Fluid Processes
[0222] Components of the present invention can be dispersed in a
supercritical fluid and crystallized as needed. Current techniques
involving supercritical fluids include precipitation by rapid
expansion of supercritical solutions, gas anti-solvent processes,
and precipitation from gas saturated solutions.
[0223] Coacervation
[0224] Coacervation is a transfer of macromolecules with film
properties from a solvated state in a coacervation phase into a
phase in which there is a film around each particle. The
coacervation method involves dispersing the composition in a
dispersion of a polymeric colloid, such as gelatin alginate, and
shock treating the mixture with temperature or pH, etc., to
generate a two-phase system. The desired phase is then hardened
with a cross-linking agent, such as glutaraldehyde.
[0225] Cryopelletization
[0226] The cryopelletization procedure allows conversion of a
molten mass, aqueous solution or suspension into solid, bead-like
particles. The molten mass solutions or suspensions are dripped by
means of an appropriately designed device into liquid nitrogen. The
production of small drops and liquid nitrogen cooling permit very
rapid and uniform freezing of the material processed. The pellets
are further dried in conventional freeze dryers. Cryopelletization
can also be carried out under aseptic conditions for sterile
processing. The most critical step producing spherical particles by
globulization is the droplet formation. Droplet formation is
influenced by formulation related variables, such as the nature of
the active ingredient and additives, viscosity, total solid
content, surface tension, etc. Extra care must be undertaken with
processing of suspensions to ensure homogeneity. In addition,
equipment design and processing variable also play an important
role. One skilled in the art can readily balance the various
factors to produce a satisfactory product. Enteric matrix pellets
can be formed that include polyacrylic acid (e.g. Carbopol) with a
high molecular weight polyethylene (such as PEG-20,000).
[0227] Other processes suitable for producing solid compositions of
the pharmaceutical compositions of the present invention include
extrusion and spray chilling. These processes are described in
detail in U.S. Pat. Nos. 5,965,161 and 5,539,000 respectively, the
disclosures of which are incorporated herein by reference.
[0228] For processing of encapsulated compositions, various methods
can be used. The term "microencapsulation" applies to enclosure or
encasement in microcapsules. Microencapsulation is a means of
applying coatings to small particles of solids or droplets of
liquids and dispersions. The terms "coated," "protected" or
"layered" are commonly used interchangeably with the term
"encapsulated." All of these terms can be used to refer to
practically any core material that is encased or enclosed in an
outer shell. Typical equipment used to apply coating includes a
conventional pan (Pellegrini; Italy), a modified perforated pan
(multicoater, Thomas Eng., IL) or a Wurster coater in a Glatt
powder doater/granulator (Glatt Airtechniques).
[0229] Solvent Based Solution Coating
[0230] Solvent-based coating is when the components of the
invention are solubilized and/or dispersed in a solvent. The
solvent can be aqueous. When the solvent is aqueous-based, the
components can be emulsified with an appropriate emulsifier,
organic solvent, or a supercritical fluid. Solvents with a lower
melting point than water and higher evaporation numbers are
preferred. Solvent mixtures with other organic solvents or water
are often employed to get appropriate viscosity and component
solubilization. Typical solvents include ethanol, methanol,
isopropanol, acetone, dichloromethane, trichloromethane and ethyl
acetate. Appropriate polymers can also be added as needed.
Cellulosic derivatives and polymethacrylates are particularly
suitable additives for organic solvent coating. Dissolution and
solubilization of the components is facilitated by rigorous
stirring or heating. Plasticizers may be also be added to stimulate
dissolution. Colorants and antisticking agents can be employed as
needed.
[0231] Substrate surface area, shape, porosity and stability are
important determinants of good coating. Spherical particles are
preferred, and these may be produced through spheronization or a
spherical crystallization process. Crystals or compact granules
from dry compaction or extrusion processes, often available
commercially, serve as good substrates.
[0232] Encapsulation can be conducted by traditional pan coating or
fluidized bed techniques. Several process (air supply, temperature,
spray rate, spray system, powder feed, attrition) and formulation
factors determine the quality of the end product, and one skilled
in the art can readily adjust such parameters as needed.
[0233] Air suspension in a rotary fluidized bed granulator can used
to deposit the encapsulation coat on to a substrate, thus allowing
a high rate of drug application with low drug loss. Furthermore,
both aqueous and organic solvents can be used. The Wurster process,
an air suspension technique, is more suitable for encapsulations
involving very fine powders.
[0234] Solvent-Free Coating
[0235] This process entails using coating materials that can be
applied in a molten state. The selection of proper coating
materials depends on melting point, melting point range and the
viscosity in the liquid state. A fluidized bed is ideal for molten
coatings of substrates that range from about 100-2000 microns in
size. Fluidized bed coating, spraying molten materials, involves
achieving a proper balance of process parameters that allow proper
encapsulation to occur. Substrate particles that are suspended and
separated from each other by the fluidization air enter a zone of
finely atomized coating liquid. Coating occurs as the liquid
droplets, which are substantially smaller in size than substrate,
impact the particles, spread, and solidify. Multiple layers can be
coated, and the completion of spraying is followed by a product
stabilization or cooling step. Some critical success parameters
include bed temperature, atomization, atomization fluid
temperature, or droplet size, spray type, spray rate, rate of
coating droplet solidification on particle surfaces, particle size,
shape, etc. Inert materials such as sodium chloride, citric acid,
potassium chloride can serve as substrates. One skilled in the art
can readily adjust such parameters to achieve a satisfactory
product.
[0236] The processes described above are suitable for treating
substrate-based compositions or non-substrate-based compositions of
the present invention. Thus, in one embodiment, pharmaceutical
compositions of the present invention do not include a seed
particle, such as a conventional drug or other additive aggregate
starch or sugar bead. Instead, the compositions are processed, and
the components are chosen, such that a solid composition is formed
without the need to coat the composition onto a substrate bead.
Such compositions can be in the form of beadlets, beads, granules,
pellets, etc., that have an approximately homogenous distribution
of active ingredient, surfactant, triglyceride and/or additives.
These compositions can be produced by means of balling in
pelletizers or fluid bed granulators, and compaction or
extrusion/spheronization. In addition, these compositions can be
produced using solvent-free spray congealing processes or dropping
(globulization) methods. Dropping procedures involve conversion of
aqueous solutions or suspensions to a solid form. Congealing of the
liquid droplets in cooling baths can aided by a chemical reaction
(e.g., insoluble salt or complex formation), a sol/gel transition,
or by freezing in a coolant bath of liquid nitrogen or halogenated
hydrocarbons.
[0237] 8. Specific Formulations
[0238] In one embodiment, the solid pharmaceutical composition
includes a solid carrier, the solid carrier including a substrate
and an encapsulation coat on the substrate. The encapsulation coat
includes at least one ionic or non-ionic hydrophilic surfactant.
Optionally, the encapsulation coat can include a pharmaceutical
active ingredient, a lipophilic component such as a lipophilic
surfactant or a triglyceride, or both a pharmaceutical active
ingredient and a lipophilic component.
[0239] Prior art has used surfactants in formulating coated bead
compositions to provide a wetting function, to enable hydrophobic
drugs to properly adhere to beads and/or water-soluble binders. For
example, U.S. Pat. No. 4,717,569 to Harrison et al. discloses
coated bead compositions of hydrophobic steroid compounds wetted by
a hydrophilic surfactant and adhered to the beads by a
water-soluble binder. The steroid compound is present as finely
divided particles, held to the beads by the binder. The present
inventors have surprisingly found that proper choice of surfactants
and other components allows compositions to be prepared with a wide
variety of active ingredients. For example, while the Harrison
reference discloses the use of surfactants as wetting agents, the
present inventors have found that surfactants at higher levels,
i.e., in amounts far in excess of the amounts necessary or
appropriate for a wetting function, enable a pharmaceutical active
ingredient to be fully or at least partially solubilized in the
encapsulation coating material itself, rather than merely
physically bound in a binder matrix. In fact, while binders can
optionally be used in the compositions of the present invention,
the higher surfactant concentrations of the present invention,
i.e., solubilizing amounts, obviate the need for binders and render
them optional instead of necessary.
[0240] The amount of hydrophilic surfactant used in this embodiment
can be adjusted so as to at least partially or fully solubilize the
pharmaceutical active ingredient, with the optional lipophilic
surfactants, triglycerides and solubilizer chosen to further
increase the pharmaceutical active ingredient's solubility.
[0241] A further advantage believed to accrue from the
pharmaceutical compositions of the present invention is that upon
administration of the composition to a patient, the high levels of
surfactants and other components present in the composition
facilitate the rapid solubilization of the pharmaceutical active
ingredient. Thus, while the prior art composition of Harrison
contains a drug in a form which requires further solubilization in
vivo, such as by emulsification and micellization in the
gastrointestinal tract, the active ingredient in compositions of
the present invention is at least partially solubilized in the
composition itself, and is further provided with surfactants and
other components in the composition to facilitate rapid dispersion
(emulsification/micellization) and sustained solubilization of the
active ingredient upon administration.
[0242] It should be noted that in this embodiment, the
encapsulation coat can alternatively be formulated without the
active ingredient. In this aspect, an active ingredient can be
provided in the composition itself but not in the encapsulation
coat, if desired. While not presently preferred, such a formulation
delivers the active ingredient to the patient along with the
surfactants or other components to facilitate dispersion
(emulsification/micellization), thus still providing more rapid
active ingredient presentation to the absorption site.
Alternatively, the active ingredient can be administered in a
separate dosage form, including a conventional dosage form, prior
to, concurrently with, or subsequent to administration of the
present compositions, to achieve similar advantages.
[0243] The optional lipophilic surfactant and triglycerides can be
used as desired to further enhance solubilization of the active
ingredient, or to promote dispersion (emulsification/micellization)
in vivo, or to promote in vivo absorption at the absorption
site.
[0244] For more hydrophilic active ingredients, the materials of
the encapsulation coat provides components to promote efficient
transport of the active ingredient across the barrier membrane to
promote more effective absorption. For these active ingredients, it
is preferable to include a lipophilic component in the
encapsulation coat.
[0245] In another embodiment, the solid pharmaceutical composition
includes a solid carrier, the solid carrier including a substrate
and an encapsulation coat on the substrate. The encapsulation coat
includes a hydrophilic surfactant. Optionally, the encapsulation
coat can include a pharmaceutical active ingredient, an ionic or
non-ionic hydrophilic surfactant, or both a pharmaceutical active
ingredient and a hydrophilic surfactant. In this embodiment, the
lipophilic surfactant or triglyceride can be present in amounts to
enable at least partial solubilization of an active ingredient in
the encapsulation coat, in the composition, or separately
administered.
[0246] In another embodiment, the solid pharmaceutical composition
effectively presents a lipophilic component with or without an
active ingredient to help promote absorption of a hydrophilic
active.
[0247] In another embodiment, the solid pharmaceutical composition
includes a solid carrier, the solid carrier including a substrate
and an encapsulation coat on the substrate. The encapsulation coat
includes a pharmaceutical active ingredient and an ionic or
non-ionic hydrophilic surfactant; a pharmaceutical active
ingredient and a lipophilic component such as a lipophilic
surfactant or a triglyceride; or a pharmaceutical active ingredient
and a lipophilic component such as a lipophilic surfactant or a
triglyceride; or a pharmaceutical active ingredient and both a
hydrophilic surfactant and a lipophilic component.
[0248] In another embodiment, the solid pharmaceutical composition
includes a solid carrier, wherein the solid carrier is formed of at
least two components selected from the group consisting of
pharmaceutical active ingredients; ionic or non-ionic hydrophilic
surfactants; and lipophilic components such as lipophilic
surfactants and triglycerides.
[0249] In this embodiment, the solid pharmaceutical composition is
formulated without the need for a substrate seed particle. The
active ingredient, surfactants and triglycerides in the chosen
combination are processed, with appropriate excipients if
necessary, to form solid carriers in the absence of a seed
substrate. Preferably, the components are chosen to at least
partially solubilize the active ingredient, as described above.
[0250] 9. Methods
[0251] The present invention also provides methods of using the
above-described pharmaceutical composition. In one aspect, the
present invention provides a method of treating a patient with an
active ingredient, the method including the steps of providing a
dosage form of a pharmaceutical composition as described above,
including an active ingredient, and administering the dosage form
to the patient. The patient can be an animal, preferably a mammal,
and more preferably a human.
[0252] In another aspect, the present invention provides a method
including the steps of providing a dosage form of a pharmaceutical
composition as described above, providing a dosage form of a
pharmaceutical active ingredient, and administering the dosage
forms to the patient. This method is advantageous when all or part
of the active ingredient or an additional active ingredient is to
be administered to the patient in a separate dosage form prior to,
concurrently with, or subsequent to administration of the
pharmaceutical composition.
[0253] In another aspect, the present invention provides a method
of improving the palatability and/or masking the taste of an active
ingredient, by providing the active ingredient in a pharmaceutical
composition as described above. Since the active ingredient is
encapsulated in a lipid coat, it will not instantaneously dissolve
in the mouth, but will instead dissolve in a region past the oral
cavity, thereby substantially avoiding or at least reducing
undesirable contact between the active ingredient and the
mouth.
[0254] In another aspect of the invention, the compositions enable
gastric resistance or acid degradation reduction of the active
ingredient.
[0255] In another aspect of the invention, the solid carrier
improves the chemical stability of the active ingredient.
[0256] In another aspect of the invention, the solid carrier
protects the upper gastrointestinal tract from the adverse effects
of the active ingredient.
[0257] In another aspect, the present invention provides a method
of improving the dissolution and/or absorption of a pharmaceutical
active ingredient, by administering the active ingredient in a
composition as described above, or co-administering the active
ingredient with a composition as described above.
EXAMPLES
Example 1
Preparation of Coated Beads
[0258] Compositions according to the present invention were
prepared as follows. The specific components used are detailed in
Examples 2-5.
[0259] A spraying solution of the coating materials was prepared by
dissolving the desired amount of the active ingredient and mixing
with the hydrophilic and/or lipophilic surfactants in an organic
solvent or a mixture of organic solvents. The organic solvent used
for the coating solution was a mixture of methylene chloride and
isopropyl alcohol in a 3:1 to 1:1 weight ratio.
[0260] Commercially available sugar beads (30/35 mesh size) were
coated in a conventional coating pan having a spray gun (Campbell
Hausfield, DH 7500) with a nozzle diameter of 1.2 mm and an air
pressure of 25 psi. The bed temperature was maintained at
approximately 32.degree. C. during the spraying process.
Appropriate amounts of talc were sprinkled on the beads during the
spraying process to reduce the agglomeration of coated beads. When
the spraying process was completed, the coated beads were allowed
to cool to room temperature. The coated beads were then dried under
vacuum to minimize residual solvent levels. The dried, coated beads
were then sieved and collected.
Example 2
Composition I
[0261] A pharmaceutical composition was prepared according to the
method of Example 1, having a substrate particle, an active
ingredient (glyburide), and a mixture of a hydrophilic surfactant
(PEG-40 stearate) and a lipophilic surfactant (glycerol
monolaurate). The components and their amounts were as follows:
TABLE-US-00020 Component Weight (g) % (w/w) Glyburide 1 0.8 PEG-40
stearate 33 25.2 Glycerol monolaurate 17 13.0 Nonpareil seed (30/35
mesh) 80 61.1
Example 3
Composition II
[0262] A pharmaceutical composition was prepared according to the
method of Example 1, having a substrate particle, an active
ingredient (progesterone), a mixture of a hydrophilic surfactant
(Solulan C-24) and two lipophilic components (deoxycholic acid and
distilled monoglycerides). The components and their amounts were as
follows:
TABLE-US-00021 Component Weight (g) % (w/w) Progesterone 12 8.6
Solulan C-24 (Amerchol)* 32 22.9 Distilled monoglycerides 8 5.7
Deoxycholic acid 8 5.7 Nonpareil seed (30/35 mesh) 80 57.1 *PEG-24
cholesterol ether
Example 4
Composition III
[0263] A pharmaceutical composition was prepared according to the
method of Example 1, having a substrate particle, an active
ingredient (itraconazole), a mixture of non-ionic hydrophilic
surfactants (Cremophor RH-40 and PEG-150 monostearate), an ionic
hydrophilic surfactant (sodium taurocholate) and a lipophilic
surfactant (glycerol monolaurate). The components and their amounts
were as follows:
TABLE-US-00022 Component Weight (g) % (w/w) Itraconazole 20 9.7
Cremophor RH-40 (BASF)* 25 12.1 Glycerol monolaurate 10 4.8 Sodium
taurocholate 5 2.4 PEG-150 monostearate 27 13.0 Nonpareil seed
(30/35 mesh) 120 58.0 *PEG-40 hydrogenated castor oil
Example 5
Composition IV
[0264] A pharmaceutical composition was prepared according to the
method of Example 1, having a substrate particle, an active
ingredient (omeprazole), a mixture of a two hydrophilic surfactants
(PEG-150 monostearate and PEG-40 monostearate), and a
triglyceride-containing lipophilic component (Maisine 35-1). The
components and their amounts were as follows:
TABLE-US-00023 Component Weight (g) % (w/w) Omeprazole 16 8.8
PEG-150 monostearate 50.4 27.8 PEG-40 monostearate 25.2 13.9
Maisine 35-1 (Gattefosse)* 8.4 4.6 Magnesium carbonate 1.6 0.9
Nonpareil seed (30/35 mesh) 80 44.1 *linoleic glycerides
Example 6
Seal Coating
[0265] The dried, coated beads of Example 3 were further seal
coated by a polymer layer. The seal coating polymer layer was
applied to the progesterone-coated beads in a Uni-Glatt fluid bed
coater. Polyvinylpyrrolidone (PVP-K30) was dissolved in isopropyl
alcohol to form a 5% w/w solution. This seal coating solution was
sprayed onto the coated beads with a Wurster bottom spray insert.
The inlet and outlet air temperature were maintained at 30 and
40.degree. C., respectively. When the spraying process was
complete, the beads were further dried by supplying dry air at
50-55.degree. C. for 5-15 minutes. The seal coated beads were then
allowed to cool in the apparatus by supplying dry air at
20-25.degree. C. for 5-15 minutes. The dried, seal coated beads
were collected and stored in a container.
Example 7
Protective Coating
[0266] The dried, coated beads of Example 5 were further coated
with a protective polymer layer. The protective coating was applied
to the omeprazole coated beads by spraying with a hydroxypropyl
methylcellulose (HPMC) solution. The protective coating HPMC
solution was prepared by dissolving 6 grams of HPMC in ethanol. To
this solution, methylene chloride was added followed by 2 mL of
triethylcitrate as a plasticizer and 1 g of talc. The HPMC solution
was sprayed on the beads as described in Example 6, and the
protective coated beads were then dried and collected.
Example 8
Enteric Coating
[0267] The dried, coated beads of Example 5 were further coated
with an enteric coating layer. The enteric layer was applied to the
omeprazole coated beads by spraying a Eudragit L100 solution.
Eudragit L100 is an acrylate polymer commercially available from
Rohm Pharma. The spraying solution was prepared by dispersing 15 g
of Eudragit L100 in 200 mL of ethanol to give a clear solution. To
this solution, 4 g of triethyl citrate was then added as a
plasticizer. 2 grams of purified talc was also added to the
solution. The solution was then sprayed onto the beads, and the
beads were dried, as described in Example 6.
Example 9
Comparative Dissolution Study I
[0268] A comparative dissolution study was performed on three forms
of an active ingredient: the glyburide coated beads of Example 2, a
commercially available glyburide product (Micronase.RTM., available
from Pharmacia & Upjohn), and the pure glyburide bulk drug. The
dissolution study was performed using a USP dissolution type 2
apparatus. For each of the three forms, material equivalent to 5 mg
of glyburide was used for each triplicated dissolution run in 500
mL of isotonic pH 7.4 phosphate buffer. The dissolution medium was
maintained at 37.degree. C. and constantly stirred at a speed of
100 rpm. The dissolution media were sampled at 15, 30, 45, 60, 120
and 180 minutes. At each time point, 3 mL of the medium was
sampled, and the medium was replenished with 3 mL of fresh buffer.
The samples were filtered through a 0.45.mu. filter immediately
after the sampling. The filtrates were then diluted in methanol to
an appropriate concentration for a glyburide-specific HPLC
assay.
[0269] The HPLC assay was performed on a Varian 9010 system by
injecting 50 .mu.L of the sample. The sample was separated on a
Phenominex C18 column by running a mobile phase of 75:25 v/v
methanol/phosphate buffer (0.1 M potassium dihydrogen phosphate, pH
adjusted to 3.5 using phosphoric acid), at a flow rate of 1 mL/min,
at ambient temperature. Glyburide was detected by its UV absorption
at 229 nm.
[0270] The results of the comparative dissolution measurement were
expressed as the percent of glyburide dissolved/released in the
dissolution medium at a given time, relative to the initial total
glyburide content present in the dissolution medium (5 mg/500 mL).
The results are shown in FIG. 1, with the error bars representing
the standard deviation. As the Figure shows, the glyburide coated
beads of the present invention showed a superior dissolution
profile in the rate, the extent, and the variability of glyburide
dissolved/released into the dissolution medium, compared to the
commercial Micronase.RTM. and the pure bulk drug.
Example 10
Comparative Dissolution Study II
[0271] A comparative dissolution study was performed on three forms
of an active ingredient: the progesterone coated beads of Example
3, the seal coated, progesterone coated beads of Example 6, and the
pure progesterone bulk drug. The dissolution study was performed
using a USP dissolution type 2 apparatus. For each of the three
forms, material equivalent to 100 mg of progesterone was used for
each duplicated dissolution run in 900 mL of isotonic pH 7.4
phosphate buffer containing 0.5% w/v of Tween 80. The dissolution
medium was maintained at 37.degree. C. and constantly stirred at a
speed of 100 rpm. The dissolution media were sampled at 30, 60, 120
and 180 minutes. At each time point, 3 mL of the medium was
sampled, and the medium was replenished with 3 mL of fresh
buffer/Tween solution. The samples were filtered through a 0.45.mu.
filter immediately after the sampling. The filtrates were then
diluted in methanol to an appropriate concentration for a
progesterone-specific HPLC assay.
[0272] The HPLC assay was performed on a Varian 9010 system by
injecting 50 .mu.L of the sample. The sample was separated on a
Phenominex C18 column by running a mobile phase of 75:25 v/v
methanol/phosphate buffer (0.1 M potassium dihydrogen phosphate, pH
adjusted to 3.5 using phosphoric acid), at a flow rate of 1 mL/min,
at ambient temperature. Glyburide was detected by its UV absorption
at 229 nm.
[0273] The results of the comparative dissolution measurement were
expressed as the percent of progesterone dissolved/released in the
dissolution medium at a given time, relative to the initial total
progesterone content present in the dissolution medium (100 mg/900
mL). The results are shown in FIG. 2A. As the Figure shows, the
progesterone coated beads of the present invention, with or without
a seal coating, showed superior dissolution profiles in both the
rate and the extent of progesterone dissolved/released into the
dissolution medium, compared to the pure bulk drug.
Example 11
Comparative Dissolution Study III
[0274] A comparative dissolution study was performed on three forms
of an active ingredient: the progesterone coated beads of Example
3, the seal coated, progesterone coated beads of Example 6, and the
pure progesterone bulk drug. Prometrium.RTM. is a capsule dosage
form in which micronized progesterone is suspended in a blend of
vegetable oils. The dissolution of the Prometrium.RTM. capsule was
performed using a USP dissolution type 1 apparatus, and the
dissolution of the other samples was performed using a USP
dissolution type 2 apparatus. For each of the three forms, material
equivalent to 100 mg of progesterone was used for each dissolution
run in 900 mL of isotonic pH 7.4 phosphate buffer. The dissolution
medium was maintained at 37.degree. C. and constantly stirred at a
speed of 100 rpm. The dissolution media were sampled at 15, 30, 45,
60 and 180 minutes. At each time point, 3 mL of the medium was
sampled, and the medium was replenished with 3 mL of fresh
buffer/Tween solution. The samples were filtered through a 0.45.mu.
filter immediately after the sampling. The filtrates were then
diluted in methanol to an appropriate concentration for a
progesterone-specific HPLC assay.
[0275] The HPLC assay was performed on a Varian 9010 system by
injecting 50 .mu.L of the sample. The sample was separated on a
Phenominex C18 column by running a mobile phase of 75:25 v/v
methanol/phosphate buffer (0.1 M potassium dihydrogen phosphate, pH
adjusted to 3.5 using phosphoric acid), at a flow rate of 1 mL/min,
at ambient temperature. Glyburide was detected by its UV absorption
at 229 nm.
[0276] The results of the comparative dissolution measurement were
expressed as the percent of progesterone dissolved/released in the
dissolution medium at a given time, relative to the initial total
progesterone content present in the dissolution medium (100 mg/900
mL). The results are shown in FIG. 2B. As the Figure shows, the
progesterone coated beads of the present invention, with or without
a seal coating, showed superior dissolution profiles in both the
rate and the extent of progesterone dissolved/released into the
dissolution medium, compared to the commercial Prometrium.RTM. and
the pure bulk drug.
Example 12
Comparative Dissolution Study IV
[0277] A comparative dissolution study was performed comparing the
rate and extent of dissolution of the protective coated, omeprazole
coated beads of Example 7, the enteric coated, omeprazole coated
beads of Example 8 and a commercially available omeprazole product
(Prilosec.RTM., available from Astra Zeneca). The dissolution study
was performed using a USP dissolution type 2 apparatus. For each of
the three dosage forms, material equivalent to 5 mg of omeprazole
was used for each dissolution run in 500 mL of isotonic pH 7.4
phosphate buffer. The dissolution medium was maintained at
37.degree. C. and constantly stirred at a speed of 100 rpm. The
dissolution media were sampled at 15, 30, 45 and 60 minutes. At
each time point, 3 mL of the medium was sampled, and the medium was
replenished with 3 mL of fresh buffer. The samples were filtered
through a 0.45.mu. filter immediately after the sampling. The
filtrates were then diluted in methanol to an appropriate
concentration for an omeprazole-specific HPLC assay.
[0278] The HPLC assay was performed on a Varian 9010 system by
injecting 50 .mu.L of the sample. The sample was separated on a
Phenominex C18 column by running a mobile phase of 30:70 v/v
acetonitrile/phosphate buffer (pH 7.4), at a flow rate of 1.1
mL/min, at ambient temperature. Omeprazole was detected by its UV
absorption at 302 nm.
[0279] The results of the comparative dissolution measurement were
expressed as the percent of omeprazole dissolved in the dissolution
medium at a given time, relative to the initial total omeprazole
content present in the dissolution medium (5 mg/500 mL). The
results are shown in FIG. 3. As the Figure shows, the omeprazole
coated beads of the present invention showed superior dissolution
profiles in both the rate and the extent of omeprazole
dissolved/released into the dissolution medium, compared to the
commercial Prilose.RTM. product.
[0280] The following non-limiting Examples 13-28 illustrate
compositions that can be prepared according to the present
invention. It should be appreciated that the compositions can be
prepared in the absence of the active ingredients and appropriate
amounts of the active ingredients in any given dosage form then can
be administered together or separately with the composition. It
should also be appreciated that the compositions can further
include additional additives, excipients, and other components for
the purpose of facilitating the processes involving the preparation
of the composition or the pharmaceutical dosage form, as described
herein, as is well-known to those skilled in the art.
Example 13
TABLE-US-00024 [0281] Component Amount (g) Atorvastatin 4 Partially
hydrogenated soybean oil 10 Myrj 52 (PEG-40 stearate) 70 Monomuls
90-45 (glyceryl monolaurate) 20 Nonpareil seed (25/30 mesh) 120
Example 14
TABLE-US-00025 [0282] Component Amount (g) Alendronate sodium 50
Cremophor RH-40 (PEG-40 hydrogenated 100 castor oil) Capmul MCM
(glyceryl 50 caprylate/caprate) Sodium alginate 2 Water 5 Nonpareil
seed (25/30 mesh) 200
Example 15
TABLE-US-00026 [0283] Component Amount (g) Ganciclovir 100
Tocopheryl PEG-1000 succinate 200 Imwitor 191 (glyceryl
monostearate) 30 Water 20 Nonpareil seed (25/30 mesh) 400
Example 16
TABLE-US-00027 [0284] Component Amount (g) Simvastatin 20
Hydrogenated castor oil 40 Crodet O40 (PEG-40 oleate) 200
Example 17
TABLE-US-00028 [0285] Component Amount (g) Zafirlukast 7 PEG-150
monostearate 50 PEG-40 monostearate 80 Peceol (glyceryl monooleate)
15
Example 18
TABLE-US-00029 [0286] Component Amount Salmon calcitonin 300,000 IU
PEG-40 monostearate 200 g Glycerol monolaurate 100 g Water 5 g
Example 19
TABLE-US-00030 [0287] Component Amount (g) Lovastatin 20 Coenzyme
Q10 50 PEG-40 stearate 150 Glycerol monolaurate 50 Nonpareil seed
(25/30 mesh) 200
Example 20
TABLE-US-00031 [0288] Component Amount (g) Tacrolimus 5 Solulan
C-24 130 Distilled monoglycerides 40 Deoxycholic acid 80 Nonpareil
seed (35/40 mesh) 250
Example 21
TABLE-US-00032 [0289] Component Amount (g) Rapamycin 20 PEG-40
stearate 150 PEG-150 stearate 50 Miglyol 812 20
Example 22
TABLE-US-00033 [0290] Component Amount (g) Pioglitazone 15 Pureco
76 20 Lutrol OP 2000 30 PEG-100 hydrogenated castor oil 100 PEG-100
oleate (Crodet O-100) 100 Nonpareil seed (25/30 mesh) 200
Example 23
TABLE-US-00034 [0291] Component Amount (g) Oxaprozin 50 Safflower
oil 25 PEG-10 soya sterol (Nikkol BYS-20) 25 Myrj 52 150 Nonpareil
seed (25/30 mesh) 300
Example 24
TABLE-US-00035 [0292] Component Amount (g) Tretinoin 50 Capmul
GMO-K 50 Sodium taurocholate 100 DPPC 50 DMPC 50
Example 25
TABLE-US-00036 [0293] Component Amount (g) Celecoxib 50 Myrj 52 100
Glycerol monolaurate 30 Hydrogenated coconut oil 20 Nonpareil seed
(25/30 mesh) 200
Example 26
TABLE-US-00037 [0294] Component Amount (g) Rofecoxib 10 Kessco PEG
1540 MS (PEG-32 stearate) 160 Imwitor 312 20 Hydrogenated palm oil
(Softisan 154) 20
Example 27
TABLE-US-00038 [0295] Component Amount (g) Fenofibrate 100 Imwitor
742 40 Imwitor 988 40 Sodium alginate 4 Crodet O-40 120 Myrj 51 120
Water 20
Example 28
TABLE-US-00039 [0296] Component Amount (g) Saquinavir 200 HPMC 50
Myrj 52 130 Arlacel 186 20
[0297] The present invention may be embodied in other specific
forms without departing from its spirit or essential
characteristics. The described embodiments are to be considered in
all respects only as illustrative and not restrictive. The scope of
the invention is, therefore, indicated by the appended claims
rather than by the foregoing description. All changes which come
within the meaning and range of equivalency of the claims are to be
embraced within their scope.
* * * * *